I think we should...

BG

Sent from my iPhone

On Jan 25, 2020, at 7:03 PM, Corbett, Kizzmekia (NIH/VRC) [E] wrote:

...
Hey Barney and Kizzmekia,

We should discuss

Cheers,

Vincent

On Jan 23, 2020, at 19:33, Corbett, Kizzmekia (NIH/VRC) [E] wrote:

Thanks Ralph & Vincent. Good luck!!! If Boyd’s on the virus cloning, I’m very confident.

Have a good night.

Sent from the mobile device of:
Kizzmekia S. Corbett, PhD
Senior Research Fellow
NIH | NIAID | VRC

From: "Baric, Ralph S" [b](6)
Date: Thursday, January 23, 2020 at 9:14:30 PM
To: "Corbett, Kizzmekia (NIH/VRC) [E]" [b](6), "Munster, Vincent (NIH/NIAID) [E]"
Subject: RE: First Wuhan Coronavirus Patient Identified in the United States
Hi Vincent,

Following up on your comment below, Ralph, you are cc’ed here because I’m gossiping about you and you can also answer this.

Cheers,
Kizzy

--

Kizzmekia S. Corbett, PhD
Senior Research Fellow
National Institutes of Health
National Institutes of Allergy and Infectious Diseases
Vaccine Research Center
Viral Pathogenesis Laboratory

Building 40 Room 2608
40 Convent Drive
Bethesda MD 20892
Laboratory: (301) 480-2771
Personal: (240) 480-2771
Fax: (301) 402-5605

From: "Munster, Vincent (NIH/NIAID) [E]" [mailto:munster@nih.gov]
Date: Tuesday, January 21, 2020 at 3:46 PM
To: "Marston, Hilary (NIH/NIAID) [E]" [mailto:marston@nih.gov], NIAID Coronavirus Response SWAT 2020 <NIAIDCoronavirusResponseSWAT2020@mail.nih.gov>
Subject: Re: First Wuhan Coronavirus Patient Identified in the United States

Quick update:
First Wuhan Coronavirus Patient Identified in the United States

A person in Washington State is infected with a new respiratory virus. The outbreak began at a market in China and now has spread to at least four other countries.

The outbreak, which has infected nearly 300 people in mainland China, began in a seafood and poultry market in Wuhan, central China. Credit...EPA, via Shutterstock

By Roni Caryn Rabin

- A person in Washington State is infected with the Wuhan coronavirus, the first confirmed case in the United States of a mysterious respiratory infection that has killed at least six people and sickened hundreds more in Asia.
The patient, who was hospitalized with pneumonia last week, recently had traveled to Wuhan, China, where the outbreak appears to have originated, federal officials have found. Investigators tested samples from the patient for the presence of the virus; positive results were received over the weekend. Officials declined to identify the patient, who was said to be quite ill. News of the first case in the United States comes amid growing evidence that the virus spreads from person to person, although it is not clear how easily.
The outbreak, which began in a seafood and poultry market in Wuhan, a city of 11 million, is spreading: Patients have been identified in Beijing, Shanghai and Shenzhen, as well as Taiwan, Japan, Thailand and South Korea.
On Tuesday, Chinese authorities confirmed that six people have died of the infection in Wuhan. Nearly 300 cases have been reported to date in China. Many of the patients lived in or traveled to Wuhan.
The World Health Organization will meet tomorrow to decide whether to declare the outbreak an international public health emergency. But information about the new virus is still thin, and it’s not clear whether or how many Americans are at risk.

“[Like the Science Times page on Facebook. | Sign up for the Science Times newsletter.]”

“There are still more questions that we don’t know the answers to than things we do know,” said Dr. William Schaffner, a professor of preventive medicine and infectious diseases at Vanderbilt University Medical Center in Nashville.

“For example, what is the source? We don’t know exactly. The location likely was the live animal market, but we don’t know the particular animal.”
The more pressing and urgent question, he said: “How frequent is human to human transmission?” In one instance a patient appears to have infected 14 health care workers in a medical facility, but that individual may have been a “super-spreader,” he said. “Could people with mild infections transmit this virus from person to person? That all remains still under investigation.”

On Monday, Vanderbilt University Medical Center in Nashville changed its electronic prompts so that any patients coming in to its hospital, emergency room or clinics with a fever or respiratory symptoms will be asked whether they have been to China recently or have had contact with anyone who has recently traveled to China.

Hospitals around the country are likely taking similar steps, Dr. Schaffner said, in an effort to quickly identify infected patients and place them in isolation so they can be cared for safely by hospital workers, and so specimens can be collected for testing.
Dr. Schaffner cautioned anyone traveling to China to avoid visiting live animal markets and to keep a distance from all live animals, including domesticated farm animals. Travelers to China should practice lots of good hand hygiene, he added, and do their best to avoid anyone who is coughing or sneezing.

The Wuhan Coronavirus Outbreak

The Test a Deadly Coronavirus Outbreak Poses to China’s Leadership
Jan. 21, 2020

China Confirms New Coronavirus Spreads From Humans to Humans
Jan. 20, 2020

Deadly Mystery Virus Reported in 2 New Chinese Cities and South Korea
Jan. 18, 2020

Three U.S. Airports to Check Passengers for a Deadly Chinese Coronavirus
Jan. 17, 2020

Japan and Thailand Confirm New Cases of Chinese Coronavirus

NIH-001011
Jan. 15, 2020

Disclaimer: Any third-party material in this email has been shared for internal use under fair use provisions of U.S. copyright law, without further verification of its accuracy/veracity. It does not necessarily represent my views nor those of NIAID, NIH, HHS, or the U.S. government.
Thank you for reaching out. I can imagine your frustration. Unfortunately, we are working at about 10% capacity at the moment because of physical distancing in the labs. We do not have room for additional people.

Best wishes in your future work.

Barney

Dear Dr. Graham,

I enjoyed your talk on COVID-19 vaccine strategies yesterday. Congratulations for an excellent talk and for your work on scientific preparedness for the current and any other potential viral pandemics.
Hi Lindsey,

Best wishes,

Barney

Sent from my iPhone

On Mar 6, 2020, at 7:09 AM, Baden, Lindsey Robert, M.D. wrote:

Barney,

Lindsey

The information in this e-mail is intended only for the person to whom it is addressed. If you believe this e-mail was sent to you in error and the e-mail contains patient information, please contact the Partners Compliance HelpLine at http://www.partners.org/complianceLine. If the e-mail was sent to you in error but does not contain patient information, please contact the sender and properly dispose of the e-mail.
FYI. Some ideas as a start.

BG
Hi Vasee,

We are only working on [attached image]

Best wishes,

Barney

Hi Barney

I hope you’re well
Would you have a summary of recent animal model work on candidate therapeutics that you could share?
With best wishes
Vasee
Thanks Alicia. We will also need an

Barney

Sent from my iPhone

On Apr 6, 2020, at 5:09 PM, Widge, Alicia (NIH/NIAID) [E] wrote:

Hi Adrian,

Alicia

DMID and Mike Busch are organizing a systematic approach to providing samples for assays
standardization and controls. I think it would be best to coordinate with that process. I’m sure we can
find a few local samples in the meantime to bridge.
From: McDermott, Adrian (NIH/VRC) [E] (b)(6)
Sent: Monday, April 6, 2020 3:27 PM
To: Graham, Barney (NIH/VRC) [E] (b)(6); Ledgerwood, Julie (NIH/NIAID) [E] (b)(6); Widge, Alicia (NIH/NIAID) [E] (b)(6)
Cc: Koup, Richard (NIH/VRC) [E] (b)(6)
Subject: Re: Sera for assay controls

Barney,

Am already in contact with Mike Busch on this – thanks for the suggestion. Anyone in the area you may have contacts with? (b)(3)

Thanks

Adrian

From: Barney Graham (b)(6)
Date: Monday, April 6, 2020 at 3:24 PM
To: "Ledgerwood, Julie (NIH/NIAID) [E] (b)(6)"; "McDermott, Adrian (NIH/VRC) [E] (b)(6)"; "Widge, Alicia (NIH/NIAID) [E] (b)(6)
Cc: Richard Koup (b)(6)
Subject: RE: Sera for assay controls

We may be able to get a panel through Mike Busch and DMID. (b)(3)
Working on it.

Julie may have other options.

Barney

From: Ledgerwood, Julie (NIH/NIAID) [E] (b)(6)
Sent: Monday, April 6, 2020 2:44 PM
To: McDermott, Adrian (NIH/VRC) [E] (b)(6); Graham, Barney (NIH/VRC) [E] (b)(6); Widge, Alicia (NIH/NIAID) [E] (b)(6)
Cc: Koup, Richard (NIH/VRC) [E] (b)(6)
Subject: RE: Sera for assay controls

NIH-001020
HI Adrian

Alicia---I know we are meeting later today on this --but how is it looking this week?

JL

From: McDermott, Adrian (NIH/VRC) [E]
Sent: Monday, April 6, 2020 2:39 PM
To: Graham, Barney (NIH/VRC) [E]<b>(6)</b> Ledgerwood, Julie (NIH/NIAID) [E]<b>(6)</b>
Cc: Koup, Richard (NIH/VRC) [E]<b>(6)</b>
Subject: Sera for assay controls

Dear All,

Any help would be appreciated

Thanks

Adrian

Adrian B McDermott, Ph.D.
Chief, Vaccine Immunology Program
Vaccine Research Center, NIAID, NIH
40 Convent Dr., Room 3508
Bethesda, MD 20892-3015
Phone (office): <b>(6)</b>
Phone (Cell): <b>(6)</b>
From: Graham, Barney (NIH/VRC) [E]
Sent: Mon, 30 Mar 2020 13:08:17 +0000
To: Embry, Alan (NIH/NIAID) [E]; Stemmy, Erik (NIH/NIAID) [E]
Subject: Fwd: COVID-19 Vaccine: Proposal & Inquiry
Attachments: COVID19 Vaccine 20200326.pdf, ATT00001.htm

FYI.
BG

Sent from my iPhone

Begin forwarded message:

From: Chad Moles <chad.moles@humanegenomics.com>
Date: March 26, 2020 at 4:40:14 PM EDT
To: "Graham, Barney (NIH/VRC) [E]" <barney.graham@nih.gov>
Subject: COVID-19 Vaccine: Proposal & Inquiry

Hi Dr. Graham,

My name is Chad Moles, and I’m the CSO of Humane Genomics, a biotech company focused on developing synthetic viruses as personalized therapeutics. You may not recall, but we met briefly at ASV 2018 at the University of Maryland. I enjoyed your discussion and thoughts on synthetic vaccinology.

Related to this, my company and I came up with a proposal for a COVID-19 vaccine. We aim to develop vesicular stomatitis virus (VSV) engineered with the spike glycoprotein of SARS-CoV-2. You can read more about it in the attached slide deck, or on our blog here and here. Of note, we received SARS-CoV-2 gene fragments today and plan to complete whole-genome assembly by Friday, bringing the design and build of vaccine candidates to 10 days.

I know you are currently collaborating with Moderna on their mRNA vaccine, but I would love to get your feedback on our vaccine proposal and learn more about how we can collaborate with government or advance our testing capabilities.

It would be great if we could setup a brief call to discuss.

Best regards,
Chad

Chad Moles, CSO @ Humane Genomics
(M) 617-521-7384; (W) humanegenomics.com

NIH-001022
Hi Victor,

Yes, I think we would like to try one of the coronaviruses that is very hard to grow in cell culture, I’ve copied Dr. Corbett here who may want to chime in.

Barney

Sent from my iPhone

On Nov 9, 2019, at 3:03 AM, Garcia-Martinez, J Victor wrote:

Hi Barney,

It was very nice to speak with you a couple of weeks ago about our mutual interest on RSV and other viruses for which our new model might be useful.

Let us know if you would like to pursue this any further.

Sincerely,

J. Victor

I’m working at home this afternoon and am relatively free except for 4-5pm. Feel free to call my cell phone.
We can then decide if it would be worth meeting at a group level.

Barney

Sent from my iPhone

On Oct 25, 2019, at 1:06 PM, Garcia-Martinez, J Victor (b)(6) wrote:

Thanks Barney.

Yes, it has been a while. Glad to reconnect in a meaningful manner.

I would very much like the opportunity to talk with you about this. Just let me know when you might be available and we can coordinate.

Sincerely,

J. Victor

From: "Graham, Barney (NIH/VRC) [E]" <(b)(6)>
Date: Friday, October 25, 2019 at 1:02 PM
To: Jose Victor Garcia Martinez (b)(6)
Subject: RE: J. Mascola suggestion RE: in vivo analysis of human immune responses to RSV

Hi Victor,

Nice to hear from you and thank you for sharing your paper. I think it has been 20 years since I was at Vanderbilt and you were at Memphis that we last spoke, although I have been following your work. Let me know if you would like to talk and I will set up a time.

Best wishes,

Barney
From: Garcia-Martinez, J Victor
Sent: Friday, October 25, 2019 12:38 PM
To: Graham, Barney (NIH/VRC)
Subject: J. Mascola suggestion RE: in vivo analysis of human immune responses to RSV

Dear Barney,

Hope you are doing well.

John Mascola visited UNC and we had the opportunity to share with him the development of an new in vivo model for the study of human respiratory pathogens. He saw our work on CMV and a little of our work on RSV. Here is the link to the paper we recently published on this:

https://www.nature.com/articles/s41587-019-0225-9

Sincerely,

J. Victor Garcia-Martinez, Ph.D.
Director, International Center for the Advancement of Translational Science
Oliver Smithies Investigator
Professor of Medicine, Microbiology and Immunology
University of North Carolina at Chapel Hill
2043 Genetic Medicine Building
120 Mason Farm Rd. CB 7042
Chapel Hill, NC 27599-7042

Phone [Redacted]
Fax (919) 843-9976
Just a reminder,

Barney

Thanks to all – I know we have much going on in parallel.

John
Hi Wing-Yun,

Can we use the title: “COVID-19: A Prototype Pathogen Demonstration Project for Pandemic Preparedness”

Barney

Sent from my iPhone

On Feb 14, 2020, at 5:50 AM, Wing-Yun Cheung wrote:

amended?

April 8*, opening talk of the emerging disease sessions

9:10 – 9:40 NIH: COVID-19 Response and preparedness
Hi Xavier,

We don’t necessarily need a call. We will be making the so just let us know what you prefer.

Best wishes,

Barney

Sent from my iPhone

On Jan 13, 2020, at 12:01 PM, Xavier Saelens wrote:

Hi Jason,

Thanks a lot for that clear advice!

All the best,

Xavier

Prof. Dr. Xavier Saelens - Principal Investigator
Hi Xavier,

Best regards,
Jason

Dear Barney,

Are you still available today at 1 pm? Not sure if we need a Skype for now and maybe better cancel it.

Jason,
Best regards,
Xavier

Prof. Dr. Xavier Saelens - Principal Investigator

VIB-UGent Center for Medical Biotechnology
Technologiepark-Zwijnaarde 71 - 9052 Ghent - Belgium
Tel: (b) (6) 71-9052
mbc.vib-ugent.be

From: "Jason McLellan" (b) (6)
To: "Xavier Saelens" (b) (6), "bgraham"
Cc: "Bert Schepens" (b) (6)
Sent: Monday, January 13, 2020 4:11:42 PM
Subject: RE: Brief Skype Coronavirus

I have a scheduling conflict at that time, but you two can go ahead and Skype and then fill me in later. In addition to (b) (4)

-Jason

From: Xavier Saelens (b) (6)
Sent: Monday, January 13, 2020 5:58 AM
To: bgraham (b) (6)
Cc: Jason McLellan (b) (6); Bert Schepens (b) (6)
Subject: Re: Brief Skype Coronavirus

Hi Barney,

1 pm (7pm here) is fine with me. Tomorrow early morning does not work for me, maybe for Bert.

Best regards,
Xavier

-
Hi Xavier,

We will be making the (b)(4) I could potentially get on a call around 1pm my time today or early tomorrow morning.

Best wishes,

Barney

Sent from my iPhone

On Jan 13, 2020, at 5:30 AM, Xavier Saelens (b)(6) wrote:

Dear Jason and Barney,

A sequence of the Wuhan CoV is now out. (b)(4)

Would you have some time later today (Jan 13) or tomorrow at 17.00h (NIH time 11.00h, Tex time 10.00h) for a brief Skype to discuss the possible options for prioritizing experiments that may or may not be included in the draft manuscript that Daniel and Dorien have been working on?

Thanks and kind regards,

Xavier
So would we still be able to do (b)(5)...

Will that be done through you, Grace or Sandra?

BG

Sent from my iPhone

On Jan 16, 2020, at 5:43 PM, Ledgerwood, Julie (NIH/NIAID) [E] wrote:

Sounds like a maybe on that issue — but would be a great opportunity for them.

Julie

On Jan 16, 2020, at 7:46 PM, Graham, Barney (NIH/VRC) [E] wrote:

Great. (b)(5)

BG

Sent from my iPhone

On Jan 16, 2020, at 4:15 PM, Ledgerwood, Julie (NIH/NIAID) [E] wrote:

Just forwarding for awareness.
DMID has agreed to hold IND.

Julie

Begin forwarded message:

From: "Beigel, John (NIH) [E]" [b] [b]
Date: January 16, 2020 at 6:28:33 PM EST
To: "Ledgerwood, Julie (NIH/NIAID) [E]" (b)(6), "Marston, Hilary (NIH/NIAID) [E]" (b)(6), "Cassetti, Cristina (NIH/NIAID) [E]" (b)(6), "Graham, Barney (NIH/VRC) [E]" (b)(6)
Cc: "Bok, Karin (NIH/VRC) [E]" (b)(6), "Chen, Grace (NIH/NIAID) [E]" (b)(6)
Subject: Re: Wuhan coronavirus vaccine study

Ok. We will discuss with the IDCRC/VTEU leadership on Tuesday. It will be a good trial by fire.

John Beigel, M.D.
Associate Director for Clinical Research
Division of Microbiology and Infectious Diseases
National Institute of Allergy and Infectious Diseases (NIAID)
Phone: (b)(5)
email: (b)(6)

From: Julie Ledgerwood (b)(6)
Date: Thursday, January 16, 2020 at 5:05 PM
To: "Marston, Hilary (NIH/NIAID) [E]" (b)(6), "Cassetti, Cristina (NIH/NIAID) [E]" (b)(6), "Graham, Barney (NIH/VRC) [E]" (b)(6), "Chen, Grace (NIH/NIAID) [E]" (b)(6)
Cc: Beigel, John (NIH) [E] (b)(6), Ledgerwood, Julie (NIH/NIAID) [E] (b)(6)
Subject: RE: Wuhan coronavirus vaccine study

Hi all

Great to hear about (b)(5) As Barney and Hilary know, (b)(5)

(b)(5)

Julie

From: Marston, Hilary (NIH/NIAID) [E] (b)(6)
Sent: Thursday, January 16, 2020 4:51 PM
To: Cassetti, Cristina (NIH/NIAID) [E] (b)(6); Graham, Barney (NIH/VRC) [E] (b)(6)
Cc: Beigel, John (NIH) [E] (b)(6); Ledgerwood, Julie (NIH/NIAID) [E] (b)(6)
Subject: RE: coronavirus vaccine study

Thanks so much for the prompt follow up. I’m looping in Julie who will be able to comment further. (+Karin as an FYI)
Hi Barney and Hilary,

I copied John Beigel, our associate director of clinical research. Do you have a sense of the timeline for initiating such trial?

As I mentioned, The kickoff meeting for this network is this coming Tuesday. If you are interested to learn about it, feel free to attend the meeting- see attached the agenda and list of investigators attending.

Cheers,
Cristina
FYI. Do we have any leads on these people?

BG

I'm guessing you are aware?

Chicago Couple With Coronavirus Discharged From Hospital, Release Statement

A husband whose wife is being treated for coronavirus is now facing the same illness at a Hoffman Estates hospital. NBC 5’s Lexi Sutter has the story.

The Chicago couple diagnosed with the coronavirus last month have been discharged from the hospital and made their first public comments on the ordeal, health officials said Friday.

The two patients - a husband and wife, both in their 60s - were released to their home "under the guidance of the Centers for Disease Control and Prevention and the Illinois Department of Public Health," a spokesman for AMITA Health said in a statement.

The patients were previously being treated at AMITA Health’s St. Alexius Medical Center in Hoffman Estates. The pair also released their first statement on the ordeal Friday.

"With it being an uncomfortable situation, the care and the services we’ve received have been great," the couple said in a joint statement released by AMITA Health. "Everyone’s been very kind and very respectful. This has been the best healthcare experience we’ve ever had, but we’re definitely looking forward to getting home and getting life back to normal."
The couple requested privacy in their transition to home isolation, health officials said. The woman was the second person diagnosed with the virus in the U.S., health officials announced on Jan. 24. She returned from Wuhan, China - the epicenter of a recent outbreak - on Jan. 13 and was later hospitalized, a state epidemiologist with the Illinois Department of Public Health said in announcing the diagnosis last month.

On Jan. 30, the CDC announced that her husband tested positive for the virus, marking the first instance of person-to-person spread in the U.S.

He had "close contact" with his wife and reported symptoms, health officials said. He was admitted to an area hospital on Jan. 28, the IDPH said, where his condition was stabilized.

"This may be concerning, but based on what we know now, our assessment remains that the immediate risk to the American public is low," Robert Redfield of the CDC said after the man was diagnosed.

Disclaimer: Any third-party material in this email has been shared for internal use under fair use provisions of U.S. copyright law, without further verification of its accuracy/veracity. It does not necessarily represent my views nor those of NIAID, NIH, HHS, or the U.S. government.
I mentioned this but I see I never sent it. This is a list of exempted people who have permission to work within the limitations on space.

Barney

Dear Dr. Graham:

The Lab Maintenance Subcommittee of the COVID-19 Response Committee has approved your exemption request titled "Work exemptions for members of VPL at NIAID VRC".

Your request is attached for reference.

Regards,

Beth

Beth Schmidt
Assistant to Dr. Steven Holland, Director, Division of Intramural Research
National Institute of Allergy and Infectious Diseases, NIH, DHHS
10 Center Drive, Rm 11N248
Bethesda, MD 20892
Phone: (b)(6)
Disclaimer:
The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. National Institute of Allergy and Infectious Diseases shall not accept liability for any statements made that are sender's own and not expressly made on behalf of the NIAID by one of its representatives.
I can do it if Kizzy doesn’t want to. She should be first choice.

Barney

Sent from my iPhone

On Mar 19, 2020, at 2:54 PM, Hiatt, Nissa (NIH/VRC) wrote:

Hi Barney and Kizzmekia,

Peter Loftus from the WSJ spoke to Dr. Fauci last month on campus and was not able to connect with the two of you because you were both offsite that day. He has circled back around and would like to speak to one of you for a print story and cover the following:

- how mRNA-1273 works and how it was designed
- Would one of you be able to help? Peter would like to interview on the phone before COB Monday and he is available over the weekend. It was offered to Dr. Fauci and he deferred to VRC. Three related WSJ stories are attached as background.

Best,
Nissa

Nissa Hiatt
Communications
Vaccine Research Center, NIAID, NIH
40 Convent Drive, Bldg 40, Room 1100
Bethesda, MD 20892

Cell (b)(6)
Office (b)(6)
Hi Barney,

Closing the loop on this podcast request. Dr. Fauci will do the Wednesday interview and the podcaster will not visit building 40. Thanks for sharing your availability. Should he have follow up questions I’ll let this group know.

Hope you have a good conference at Fisher’s Lane.

Best,
Nissa

On Feb 15, 2020, at 4:17 PM, Graham, Barney (NIH/YRC) [E] (b)(6) wrote:

I’ll be at Fishers Lane on Wednesday for the EV-D68 workshop that we set up. It is a two day meeting. There might be time at the lunch break, but I’m not sure I would have time to drive back and forth.

Barney

Sent from my iPhone

On Feb 14, 2020, at 7:19 PM, Hiatt, Nissa (NIH/VRC) [C] (b)(6) wrote:

Hi Barney,

Peter Loftus with the Wall Street Journal will interview Dr. Fauci on Wednesday, Feb. 19 at NIH. He’d also like to speak to you about coronavirus vaccine research while he’s on campus.

If you are interested in this request, do you have time on Wednesday either before or after Dr. Fauci’s 1:30-2 PM interview? Peter would walk over to Building 40 from 31 or vice versa depending on timing so he should probably wrap up at Building 40 by 1 or arrive at Building 40 at 2:30 on the earliest side of that window.
Thank you and hope you are doing well!

Best,
Nissa

**Nissa Hiatt**
Communications
Vaccine Research Center, NIAID, NIH
40 Convent Drive, Bldg 40, Room 1100
Bethesda, MD 20892

(b) (6)

<bimage001.png>

</mime-attachment>

</mime-attachment>

</mime-attachment>
From: Graham, Barney (NIH/VRC) [E]  
Sent: Wed, 4 Mar 2020 02:35:54 +0000  
To: Kormann, Carolyn  
Subject: Re: Interview with the New Yorker?

Barney

Sent from my iPhone

On Mar 3, 2020, at 9:24 PM, Kormann, Carolyn <carolyn_kormann@newyorker.com> wrote:

That works -- many thanks! I can call you then. What is the best number?

On Tue, Mar 3, 2020 at 8:55 PM Graham, Barney (NIH/VRC) [E] <[b][6] wrote:
I could speak with you at about 7:30am EST if that works for you.
Barney Graham

Sent from my iPhone

On Mar 3, 2020, at 5:04 PM, Kormann, Carolyn <carolyn_kormann@newyorker.com> wrote:

Dear Dr. Barney Graham,
I apologize for the email out of the blue. I’m working on a story about the race to develop a COVID-19 vaccine, and I was hoping I could speak with you about the vaccine technologies currently being pursued, and how this effort compares with vaccine R&D for other outbreaks. If you have time this evening (sorry, I know it’s late in the day), that’d be great. My deadline is tomorrow afternoon.
Thanks so much.
Best,
Carolyn

Carolyn Kormann
Staff Writer

The New Yorker
1 World Trade Center
New York, NY 10007
o: 212-286-7976

NIH-001044
Carolyn Kormann  
Staff Writer  
The New Yorker  
1 World Trade Center  
New York, NY 10007  
O: 212-286-7976  
c: (b) (6)
Hi Bob,

Those text slides are from Marion Gruber at FDA, so please don’t forward those. Thanks for your help.

Barney
I prefer that we do the \textit{(b) (5)}. Would need to make sure you and others have done the courses necessary to work with \textit{(b) (5)}.

Barney

What are your thoughts? Adrian or us, honestly...

--

\textbf{Kizzmekia S. Corbett, PhD}

Senior Research Fellow | Scientific Lead

\textbf{Coronavirus Vaccines & Immunopathogenesis (coVip) Team}

Viral Pathogenesis Laboratory | Vaccine Research Center

National Institutes of Allergy and Infectious Diseases

National Institutes of Health

Building 40 Room 2608

40 Convent Drive

Bethesda MD 20892

Laboratory: \textit{(b) (6)}

Personal: \textit{(b) (6)}

Fax: (301) 480-2771

We should be doing the \textit{(b) (5)}.

BG
So is Adrian...
Sounds like another virologist in the making.

Keep well my learned friend

Here is a short ppt and a short description of the biology.

How about the abbreviated version today by email. I am ending a bit early today and much of the day a sump on Bart’s IPCAVD so re the long version this weekend best if not then next week; everyday seems like Sunday or everyday is like Monday who knows. I am happy to join whatever show you are setting up so you don’t have to do this so often.
Hi Larry,

I have an abbreviated slide deck on this subject and a much longer version from 25 years of RSV vaccine enhanced illness work. May not be fully discernible without the elevator talk. Are there other people that need to hear it? That’s what I was alluding to when I mentioned the Zoom option to Mike.

Barney

Sent from my iPhone

On Apr 8, 2020, at 11:03 AM, Corey MD, Larry (b)(6) wrote:

John tells me you have a slide deck you show people about enhancement; working on a synopsis about vaccine approaches for Tony so would love to see the deck; perhaps I should hear the elevator speech from you first hand. or both.

You have my cell or give me a time
I'm usually on this call, so if we can push lab meeting that would be best.

BG

Hi Dr. Graham --

I don't think you attend these calls. If so, please let me know. They changed the time this week. It conflicts with Lab Meeting tomorrow – which I can push back to 11:00 am – 12:00 pm if needed.

Thanks...Monique
Hello all

Last week we talked about having the developers call on the 15th, but that will instead be on the 22nd. This week we will have presentations from Cassandra Kelly at FIND and from Le Sun from AnyGo technology. A pre-print and other materials from Dr. Sun will be placed on the shared drive.

Bill
Conference ID: (b) (6)

Forgot your dial-in PIN? Help

Click "Help" for more ways to join the Meeting
No problem Bart. is one of the last boxes to check. Everything else has gone about as smoothly and rapidly as I could hope for.

Barney

Sent from my iPhone

On Feb 17, 2020, at 6:26 PM, Barton Haynes, M.D. wrote:

Hi Barney; I cant tell you how much we appreciate your help with . We will keep you informed and if anything we do can be of help to you just let us know. All the very best Bart

Sent from the mobile device of:
Kizzmekia S. Corbett, PhD
Senior Research Fellow
coVip Scientific Lead
VRC | NIAID | NIH
Many thanks Barney

Also who would we talk to about

All the very best Bart

Hi Bart. I’ll make sure your lab is also on the list

Best wishes,

Barney
Hi Barney:

All the very best Bart

Barton F. Haynes, M.D.
Director, Duke Human Vaccine Institute
Frederic M. Hanes Professor of Medicine and Immunology
2 Genome Court
MSRBII Bldg. Room 4090
DUMC 103020
Duke University Medical Center
Durham, NC 27710
Ph: 919-684-5230
Fx: 919-684-5230
Hi Kizzmekia,

I need to send an email like the following back to Sarah Austin. Could you look through and add other people where indicated?

Thanks,

Barney

**********************************************************
Barney S. Graham, MD, PhD
Senior Investigator
Deputy Director, Vaccine Research Center
Chief, Viral Pathogenesis Laboratory
National Institute of Allergy and Infectious Diseases, NIH
40 Convent Drive, MSC 3017
Bldg 40, Room 2502
Bethesda, MD 20892-3017
Phone: (b)(6)
URL: https://www.niaid.nih.gov/research/barney-graham-md-phd

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. National Institute of Allergy and Infectious Diseases shall not accept liability for any statements made that are sender's own and not expressly made on behalf of the NIAID by one of its representatives.
Agree.

Barney

Sent from my iPhone

On Mar 23, 2020, at 10:57 AM, Bok, Karin (NIH/VRC) [E] wrote:

Judy,

Thank you!

Karin.

Karin Bok, MS, PhD
Senior Advisor, Vaccine Development
Office of the Director, Vaccine Research Center
National Institute of Allergy and Infectious Diseases
National Institutes of Health
phone: (b)(6) mobile: (b)(6) email: (b)(6)
https://www.niaid.nih.gov/about/vrc

<image001.jpg>
Sounds like a good idea to me.

Barney

Sent from my iPhone

On Mar 20, 2020, at 4:25 PM, Routh, Jennifer (NIH/NIAID) [E] wrote:

Sorry if this one was already addressed, but I’m wondering if this would be better suited for someone like Dr. Kanta Subbarao who is at one of the WHO Collaborating Centres and could speak to flu surveillance.

Jennifer Routh [E]
News and Science Writing Branch
Office of Communications and Government Relations
National Institute of Allergy and Infectious Diseases (NIAID)
NIH/HHS
31 Center Drive Room 7A17C
Bethesda, MD 20892
Direct: (b)(6)
Hi Dr. Graham:

I’m a reporter at FiveThirtyEight working on a story about the regular seasonal influenza this year and how it has interacted with the COVID-19 outbreak. I was wondering if you might be free for a brief phone interview early next week to go over what we know about how the seasonal flu had been progressing prior to COVID-19 and how the new coronavirus complicates monitoring and controlling seasonal flu.

Please let me know if we can arrange a time to chat.

Kind regards,

Kaleigh
From: Graham, Barney (NIH/VRC) [E]
Sent: Tue, 24 Mar 2020 14:49:27 +0000
To: Corbett, Kizzmekia (NIH/VRC) [E]; (b) (6)
Subject: RE: Greetings from Fellow M - NIAID Response to COVID-19

Thank you. I also appreciate the willingness and interest to help. Unfortunately, we do not have space or an administrative mechanism to bring on more people. We are already having to rotate and to take shifts among current staff to maintain the physical distancing requirements.

Take care,

Barney

From: Corbett, Kizzmekia (NIH/VRC) [E] (b) (6)
Sent: Tuesday, March 24, 2020 10:43 AM
To: (b) (6)
Cc: Graham, Barney (NIH/VRC) [E] (b) (6)
Subject: Re: Greetings from Fellow M - NIAID Response to COVID-19

Thanks for your email. I am under the impression that with our closed campus and inability to hire or bring on special volunteers that this may not be possible. My PI, Dr. Barney Graham, can comment otherwise if apt.

Thanks tremendously for contacting us.

--

Kizzmekia S. Corbett, PhD
Senior Research Fellow | Scientific Lead
Coronavirus Vaccines & Immunopathogenesis (coVip) Team
Viral Pathogenesis Laboratory | Vaccine Research Center
National Institutes of Allergy and Infectious Diseases
National Institutes of Health

Building 40 Room 2608
40 Convent Drive
Bethesda MD 20892
Laboratory: (b) (6)
Personal: (b) (6)
Fax: (301) 480-2771
Dear Kizzmekia,

My name is [Redacted]. I wanted to send my warmest congratulations on the work you have been doing and say how proud we are of how you’ve been representing. Keep it up!

I also am writing to get your help and guidance. My colleagues (scientists) and I have been thinking of ways to assist in this crisis. I received the message (below) from a good friend and researcher in Boston. Do you know if NIAID would accept this type of information? Or, perhaps the communications department?

Certainly, there are many aspects of federal operations and response that make it different from the state level. But, I was wondering if NIH would accept this voluntary information of people with relevant skills that want to help, and if there was a particular department that would handle it. There may be other initiatives you’re of that may be more suitable. Any guidance would be appreciated.

Be Well,

[Redacted]

Hey I made a google form and more than 6,000 people responded and now I need to get it into the hands of decision makers. Know anyone at NSF who is trying to get their hands on this info? We have a few states using the database, but nothing yet at the federal level.

https://tinyurl.com/COVID19SciVolunteers
https://tinyurl.com/COVID19SciVolunteersFAQ
... and the

Barney

Sent from my iPhone

On Apr 23, 2020, at 11:50 AM, Hirsch, Marie (NIH/VRC) [E] wrote:

Hi Sarah,

(b) is a contractor so I will take her off of this list. We will check with the Bridget and Patrick is there is a way to recognize contractors. Thanks.

Marie

Good afternoon Marie – forwarding the below nomination on Barney’s behalf.

NIH-001072
Thank you,
Sarah
I think

BG

Okay, apparently

On Thu, Jan 23, 2020 at 7:14 AM
Hi Barney,

I have no idea who this person is. Do you know them? Any interest in working together?

I’ll follow your lead here, as we are just supporting your efforts on Coronavirus nanoparticles.

---------- Forwarded message ----------
Hi 

Luckily is already working on a vaccine which is great! Please discuss with him.

> On Jan 23, 2020, at 2:35 AM,
> Hi 
> I’m so sorry to send you the letter in the mid-night. I’m very sad that Wuhan cov spreads so rapidly.
As you know, I come from the biggest hospital in China, and we have the special medical center for infection disease.
Hi Allison,

He has a good understanding of these issues.

Interesting times. We are lucky this didn’t happen in 2003 with the first SARS. At that time we didn’t even have the technology to have virtual meetings.

Take care,

Barney

Sent from my iPhone

On Mar 31, 2020, at 7:29 AM, Allison August <mailto:Allison_August@moderna.com> wrote:

Dear Barney,

Hope that all is well by you! Thanks for your leadership during these unprecedented times! As stated by Stephane, we are sad yet completely understand. Barney, could you recommend a (non-NIH) colleague to step in here? Ideally, someone who shares your understanding of the risks for enhanced disease. Thank you!

Best,

Allison August, MD

Senior Director, Clinical Development, Infectious Diseases | Moderna Therapeutics

<br>
From: Stephane Bancel (b)(6) >
Sent: Monday, March 30, 2020 2:15 PM
To: Graham, Barney (NIH/VRC) [E] (b)(6) >; Lavina Talukdar (b)(6)
Cc: Chasen Richter (b)(6) >; Allison August (b)(6) >; Nancy McAdams (b)(6) >
Subject: Re: April 14, MERS and CoV-2

Hello, that is sad, but we understand it is not your choice.

Thank you

Speak soon

Cheers

stephane

From: "Graham, Barney (NIH/VRC) [E]" (b)(6)>
Date: Monday, March 30, 2020 at 2:07 PM
To: Lavina Talukdar (b)(6) >, Stephane Bancel (b)(6) >
Cc: Chasen Richter (b)(6) >, Allison August (b)(6) >, Nancy McAdams (b)(6) >
Subject: RE: April 14, MERS and CoV-2

Hi Stephane,

I’ve been advised by the Ethics office not to participate in this. I think before January 10th it was not so complicated, but with the active licensing and other activities it is viewed as unadvisable.

Sorry about that. Probably best if I focus on the task at hand anyway.

Take care,

Barney
Hi Barney,

Great to e-meet you. Thank you so much for your participation. Below is the invite with details for the event.

An outline of the topics to cover on MERS preclinical and SARS-CoV-2 is below. If you can share slides for your part of presentation by April 1\textsuperscript{st} that would be great. Also just in case, you end up having other commitments on April 14\textsuperscript{th}, the day of our Vaccines Day event, can I suggest that we do record you beforehand? We would only need your voice-over to your slides and we can play it during your segment with the slides (there won’t be video). If you are okay with that, I can work with you on setting up a day for a recording the week of April 6\textsuperscript{th}. How does that sound?

Here is the invite with details as well.

<image008.jpg>

Lavina Talukdar, CFA
Head of IR, Moderna
From: Stephane Bance <b>(6)>
Date: Wednesday, March 25, 2020 at 12:32 PM
To: "Graham, Barney (NIH/VRC) [E]" <b>(6)
Cc: Lavina Talukdar <b>(6)>
Subject: Re: April 14, MERS and CoV-2

Thanks a lot

I really appreciate it

If you could present your work on MERS and CoV to date, it would be great

Lavina copied here will help with slides, format, agenda,...

Cheers

Stephane

From: "Graham, Barney (NIH/VRC) [E]" <b>(6)>
Date: Wednesday, March 25, 2020 at 12:31 PM
To: Stephane Bance <b>(6)
Cc: Lavina Talukdar <b>(6)
Subject: Re: April 14, MERS and CoV-2

I think I can still do this. If it looks like there will be a time conflict we can record, but I'm pretty sure I can work this out.

Barney

Sent from my iPhone

On Mar 25, 2020, at 12:04 PM, Stephane Bance <b>(6) wrote:

Barney, are you still ok to present scientific data pre-clinical?
It will be online: voice + slides

April 14, but we could pre record you

Thanks a lot

Stephane

Please consider the environment before printing this email

Confidentiality notice and disclaimer: The information in this message and any attachments is intended for the exclusive use of the addressee(s), is confidential and may be privileged or otherwise protected from disclosure. Any review, retransmission, dissemination or other use of, or taking of any action in reliance upon, of any such information by persons or entities other than the intended addressee(s) is prohibited. If you have received this message in error and are not the intended addressee, please notify the sender immediately and delete this message and any attachments from your system without reading or disclosing them. If you are not the intended addressee, be advised that any use of the information in this message and any attachment is prohibited and may be unlawful, and you must not copy this message or attachment or disclose the contents to any other person.
moderna
Cordially invites you to
Vaccines Day
Tuesday, April 14, 2020
8:30am to 1:30pm EDT
(virtual only event)

Webcast presentation will be available in the Investors section of the Moderna website
Please RSVP to receive dial-in information for live Q&A
RSVP@moderatx.com

NIH-001081
Thanks Joel.

Thanks for the chance to vent (and publish).

Take care,

Barney

Sent from my iPhone

On Apr 28, 2020, at 7:47 PM, Joel Blankson wrote:

Hi Barney,
I love the article! It makes so much sense. Thank you so much for doing it.
It would be nice to work on some of these problems.
Anyway, I hope you’re getting some rest.
Best,
Joel

Hi Lisa,
Thank you for your comments and for relatively minimal edits. I liked your one sentence summary and I changed the section titles a little but kept to less than 9 words. I also answered the conflict of interest questions and filled out the acknowledgements. Let me know if we need to add the patent statement to the acknowledgements.

We appreciate the opportunity to publish in JCI.
Hi Barney,

Thank you so much for writing this excellent Commentary for us! The Board found the piece very interesting. I have attached some suggested edits, most of which serve to conform to JCI style and grammar guides. Please go through and add additional edits to this document. Please have your final text to me by Tuesday, April 28th.

Cheers,
Lisa

On 4/16/20 3:41 PM, Graham, Barney (NIH/VRC) [E] wrote:
Dear Lisa,

Please find a brief commentary attached reviewing some of our thoughts on COVID-19 and pandemic preparedness.

Thank you for the opportunity to publish in the Journal of Clinical Investigation. Please let me know if you need any additional information. If there are going to be any publication charges I would need to know prior to acceptance.

Best wishes and take care,
Barney

*******************************************************************************
Barney S. Graham, MD, PhD
Senior Investigator
Deputy Director, Vaccine Research Center
Chief, Viral Pathogenesis Laboratory
National Institute of Allergy and Infectious Diseases, NIH
40 Convent Drive, MSC 3017
Bldg 40, Room 2502
Bethesda, MD 20892-3017

NIH-001083
The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. National Institute of Allergy and Infectious Diseases shall not accept liability for any statements made that are sender’s own and not expressly made on behalf of the NIAID by one of its representatives.

--
Lisa Conti, Ph. D.
Assistant Science Editor
The Journal of Clinical Investigation
science_editor@the-jci.org
Larry is at Emory in Atlanta. Jim is in Nashville. [b (d)]

Barney

Hi everyone,

Thanks,

Judy

Thank you.

Lja

Larry J. Anderson, MD
Division of Pediatric Infectious Diseases
Emory - Children's Center
2015 Uppergate Drive, Room 530
Atlanta, GA 30322
Tel. [b (d)]
Cell [b (d)]
404-727-8249 (fax)
From: Graham, Barney (NIH/VRC) [E]  
Sent: Sunday, February 23, 2020 6:50 PM  
To: Anderson, Larry J (b) (6)  
Cc: Stein, Judy (NIH/VRC) [C] (b) (6); Corbett, Kizzmekia (NIH/VRC) [E] (b) (6)>; Morabito, Kaitlyn (NIH/VRC) [E] (b) (6)>; Bok, Karin (NIH/VRC) [E] (b) (6)  
Subject: Re: [External] RE: 2019 CoV

Hi Larry,

I bet you are glad not to be at the CDC during this one. It’s been non-stop.

Best wishes,

Barney

Sent from my iPhone

On Feb 23, 2020, at 2:11 PM, Anderson, Larry J (b) (6) wrote:

The outbreak seems to be expanding globally, in a concerning, though not surprising fashion.

thanks.

lja

Larry J. Anderson, MD  
Division of Pediatric Infectious Diseases  
Emory - Children's Center  
2015 Uppergate Drive, Room 530  
Atlanta, GA 30322  
Tel: (b) (6)  
Cell (b) (6)  
404-727-8249 (fax)
Hi Larry,

Yes, we are in the middle of it.

Barney

Barney,

Hope you are doing well and

Question.

Thanks.

Ija  
Larry J. Anderson, MD  
Division of Pediatric Infectious Diseases  
Emory - Children's Center  
2015 Uppergate Drive, Room 530  
Atlanta, GA 30322  
Tel. (b)(6)  
Cell (b)(6)  
404-727-8249 (fax)
or copying of this message (including any attachments) is strictly prohibited.

If you have received this message in error, please contact the sender by reply e-mail message and destroy all copies of the original message (including attachments).
From: Graham, Barney (NIH/VRC) [E]
Sent: Mon, 20 Apr 2020 02:30:22 +0000
To: Chang, Lauren (NIH/VRC) [F]; Ruckwardt, Tracy (NIH/VRC) [E]; Abiona, Olubukola (NIH/VRC) [F]; Corbett, Kizzmekia (NIH/VRC) [E]; Morabito, Kaitlyn (NIH/VRC) [E]; Phung, Emily (NIH/VRC) [E]
Subject: RE: (b) (5) Graphs

Thanks Lauren,

BG

From: Chang, Lauren (NIH/VRC) [F]
Sent: Sunday, April 19, 2020 9:57 PM
To: Ruckwardt, Tracy (NIH/VRC) [E]; Abiona, Olubukola (NIH/VRC) [F]; Corbett, Kizzmekia (NIH/VRC) [E]; Morabito, Kaitlyn (NIH/VRC) [E]; Graham, Barney (NIH/VRC) [E]; Phung, Emily (NIH/VRC) [F]
Subject: Re: (b) (5) Graphs

Hi Tracy,

Best,
Lauren
Looks good, Lauren. Not sure what

Tracy

Hi all,

Please find attached a slide deck summarizing our
Please let me know if you have any questions!

Best,
Lauren
Sent from the mobile device of:
Kizzmekia S. Corbett, PhD
Senior Research Fellow
coviP Scientific Lead
VRC | NIAID | NIH

From: "Abiona, Olubukola (NIH/VRC) [F]"
Date: Saturday, April 18, 2020 at 3:59:06 PM
To: "Corbett, Kizzmekia (NIH/VRC) [E]" , "Ruckwardt, Tracy (NIH/VRC) [E]" , "Graham, Barney (NIH/VRC) [E]"
Cc: "Morabito, Kaitlyn (NIH/VRC) [E]" , "Phung, Emily (NIH/VRC) [F]"
Subject: RE: (b)(5) Graphs

Emily has been forwarding me the emails. All I need is

-Olu

From: Corbett, Kizzmekia (NIH/VRC) [E] <
Sent: Saturday, April 18, 2020 3:23 PM
To: Ruckwardt, Tracy (NIH/VRC) [E] , Graham, Barney (NIH/VRC) [E]
Cc: Morabito, Kaitlyn (NIH/VRC) [E] , Phung, Emily (NIH/VRC) [F] , Abiona, Olubukola (NIH/VRC) [F]
Subject: Re: (b)(5) Graphs

Sounds good.
Yes, I will coordinate with Olubukola (& all), who I just realized was not on these emails, re: (b)(5)

Sent from the mobile device of:
Kizzmekia S. Corbett, PhD
Senior Research Fellow
covVip Scientific Lead
VRC | NIAID | NIH

From: "Ruckwardt, Tracy (NIH/VRC) [E]" (b)(6)
Date: Saturday, April 18, 2020 at 3:04:03 PM
To: "Graham, Barney (NIH/VRC) [E]" (b)(6), "Corbett, Kizzmekia (NIH/VRC) [E]" (b)(6)
Cc: "Morabito, Kaitlyn (NIH/VRC) [E]" (b)(6), "Phung, Emily (NIH/VRC) [F]" (b)(6)
Subject: Re: (b)(5) Graphs

Yes, I think this is very possible. I think the first step may be something like a

From: "Graham, Barney (NIH/VRC) [E]" (b)(6)
Date: Saturday, April 18, 2020 at 1:31 PM
To: "Corbett, Kizzmekia (NIH/VRC) [E]" (b)(6), "Ruckwardt, Tracy (NIH/VRC) [E]" (b)(6)
Cc: "Morabito, Kaitlyn (NIH/VRC) [E]" (b)(6), "Phung, Emily (NIH/VRC) [F]" (b)(6)
Subject: RE: (b)(5) Graphs

If we could do (b)(5) Graphs

BG

NIH-001107
I agree that this is a great idea, Tracy.

--

Kizzmekia S. Corbett, PhD
Senior Research Fellow | Scientific Lead
Coronavirus Vaccines & Immunopathogenesis (coVip) Team
Viral Pathogenesis Laboratory | Vaccine Research Center
National Institutes of Allergy and Infectious Diseases
National Institutes of Health

Building 40 Room 2608
40 Convent Drive
Bethesda MD 20892
Laboratory:
Personal:
Fax: (301) 480-2771

Is it possible that
so I’m not sure what to make of that.

From: "Graham, Barney (NIH/VRC) [E]" [b (6)]
Date: Friday, April 17, 2020 at 6:11 PM
To: "Corbett, Kizzmekia (NIH/VRC) [E]" [b (6)]
Cc: "Ruckwardt, Tracy (NIH/VRC) [E]" [b (6)]
Do you think there is any chance that we reversed the IgG1 and IgG2a results. It seems very odd to me especially in the C57 that there is virtually no IgG2a response, and this is a more Th1 oriented strain than BALB/c. Is there a way to check and be sure. This just doesn’t seem right.

Barney

---

Kizzmekia S. Corbett, PhD
Senior Research Fellow | Scientific Lead
Coronavirus Vaccines & Immunopathogenesis (coVip) Team
Viral Pathogenesis Laboratory | Vaccine Research Center
National Institutes of Allergy and Infectious Diseases
National Institutes of Health

Building 40 Room 2608
40 Convent Drive
Bethesda MD 20892
Laboratory: (301) 761-7610
Personal: (b)(6)
Fax: (b)(6)
Attached is the attached below).

Please let me know if you want me to change anything!

Thank you,
Emily
By the way, we have the (b)(4) that we will be working on ASAP. We will keep you up on our progress.

Barney

Sent from my iPhone

On Mar 6, 2020, at 6:34 AM, Graham, Barney (NIH/VRC) [E] wrote:

OK. Sorry to hear that. Be careful.
Our vaccine trial with Moderna will begin next week in Seattle.
Barney

Sent from my iPhone

On Mar 5, 2020, at 10:27 PM, Helen Y Chu wrote:

He’s (b)(6)

Thanks Helen.

You know that if one of these patients is willing we can fly them to NIH and apherese them so all parties can receive the cells.

Barney
On Mar 5, 2020, at 8:00 PM, Helen Y Chu wrote:

We enrolled another patient today. Will reach out and coordinate biospecimens shortly.

From: "Graham, Barney (NIH/VRC) [E]" <(b)(6)>
Date: Tuesday, March 3, 2020 at 3:28 AM
To: Helen Y Chu <(b)(6)>
Cc: "Morabito, Kaitlyn (NIH/VRC) [E]" <(b)(6)>
Subject: Re: Proposing a concept for monoclonal antibody trials as part of VTEU

Hi Helen.

Sorry to hear about the hot-spot in Seattle. Let us know if we can do more than [b](4)

Stay well.

Barney

Sent from my iPhone

On Mar 3, 2020, at 2:28 AM, Helen Y Chu wrote:

Thanks Barney, and sorry for the delay. Things in Seattle suddenly got much busier than I imagined possible.

Helen

Helen Y Chu, MD MPH
Division of Allergy & Infectious Diseases
*New lab address*
Hi Helen,

We would be glad to help as we can. However our focus is on vaccine and assay development. The VRC will be facilitating but not manufacturing a MAB in that timeframe. Some of our collaborating partners through DARPA May be, so we will see.

Barney

Sent from my iPhone

---

On Feb 27, 2020, at 12:12 AM, Helen Y Chu wrote:

Hi Barney and Kaitlyn,

We'd like to

Thanks for considering. Happy to talk on the phone.

Helen
Helen Y. Chu, MD MPH
Division of Allergy & Infectious Diseases
chulab.org
*Our lab has moved to a new location in South Lake Union*
Hi Kizzy,

Have we reviewed the (b) (4), (b) (5) Can we discuss this in the morning to make sure we are on the right path.

BG

---

From: Corbett, Kizzmekia (NIH/VRC) [E] (b)(6)
Sent: Friday, March 6, 2020 6:47 PM
To: Gall, Jason (NIH/VRC) [C] (b)(6)
Cc: Mascola, John (NIH/VRC) [E] (b)(6) ; Corbett, Barney (NIH/VRC) [E] (b)(6)
Subject: Fwd: Korea Tracking Number Shipment-FedEx Shipment (b)(4) Notification

Jason, I’m mobile but I wanted you to have the sequence now. See attached zip, & disregard the additional items unless of course you are interested.

Sent from the mobile device of:
Kizzmekia S. Corbett, PhD
Senior Research Fellow
coVip Scientific Lead
VRC | NIAID | NIH (b)(6)

---

From: "Corbett, Kizzmekia (NIH/VRC) [E]" (b)(6)
Date: Friday, March 6, 2020 at 1:36:52 PM
To: "최선호" (b)(6)
Cc: "김성순" , "최병선" , "이주연" , "이한섭" , "Stein, Judy (NIH/VRC) [C]" (b)(6)
Subject: Re: Korea Tracking Number Shipment-FedEx Shipment (b)(4) Notification

Please find all the info you need attached.

---

NIH-001115
Dear Dr. Corbett,

Thank you for updating shipment. Would you please send me the [b][6]Jagnhoon[b][6].

Jagnhoon

Kizzmekia S. Corbett, PhD
Senior Research Fellow | Scientific Lead
Coronavirus Vaccines & Immunopathogenesis (coVip) Team
Viral Pathogenesis Laboratory | Vaccine Research Center
From: "Abiona, Olubukola (NIH/VRC) [F]"  
Date: Thursday, March 5, 2020 at 4:22 PM  
To: Kizzmekia Corbett  
Subject: Korea Tracking Number Shipment - FedEx Shipment Notification

---

From: TrackingUpdates@fedex.com  
Sent: Thursday, March 5, 2020 4:17 PM  
To: Abiona, Olubukola (NIH/VRC) [F]  
Subject: FedEx Shipment Notification

---

his shipment is scheduled to be sent on 03/05/2020.

The delivery date may be updated when FedEx receives the package.

See "Preparing for Delivery" for helpful tips.

Tracking #: 

Estimated delivery date: Mon, 3/9/2020 by 8:00 PM

Initiated by: DON CHOI, PHD, DIV OF VIRAL DISEASES RESE,
Shipment Facts

Tracking number: (b)(4)

Reference: 

Service type: International Priority®

Packaging type: Your Packaging

Number of pieces: 1

Weight: 6.00 lb.

Special handling/Services: Deliver Weekday

Dry Ice

Please do not respond to this message. This email was sent from an unattended mailbox. This report was generated at approximately 3:16 PM CST on 03/05/2020.

All weights are estimated.

The shipment is scheduled for delivery on or before the scheduled delivery displayed above. FedEx does not determine money-back guarantee or delay claim requests based on the scheduled delivery. Please see the FedEx Service Guide for terms and conditions of service, including the FedEx Money-Back Guarantee, or contact your FedEx customer support representative.

To track the latest status of your shipment, click on the tracking number above.

© 2020 Federal Express Corporation. The content of this message is protected by copyright and trademark laws under U.S. and international law. Review our privacy policy. All rights reserved.

Thank you for your business.
Thanks Adrian. I’m very interested. I tried to

Barney

Sent from my iPhone

On Apr 6, 2020, at 5:39 PM, McDermott, Adrian (NIH/VRC) [E] wrote:

Barney,

Will include you in the future.
Adrian

On Apr 6, 2020, at 4:13 PM, Graham, Barney (NIH/VRC) [E] wrote:

Hi Adrian,

It might be helpful if you include me on your COVID-19 assay emails.
Hi Adrian,

This is helpful. Adding Barney here – and Hilary Marston for awareness.

I think...""
Lots and lots of work summarized very quickly.

Adrian

Adrian B McDermott, Ph.D.
Chief, Vaccine Immunology Program
Vaccine Research Center, NIAID, NIH
40 Convent Dr., Room 3508
Bethesda, MD 20892-3015
Phone (office): (b) (6)
Phone (Cell): (b) (6)
FYI. This was submitted to Science this morning and will be posted to BioRxiv in the next day or two. PDB structures are posted and should be available in next few days.

Barney
I’ve forwarded your inquiry to DMID where they are processing these kinds of requests.

Barney Graham

Sent from my iPhone

On Mar 26, 2020, at 4:40 PM, Chad Moles wrote:

Hi Dr. Graham
My name is Chad Moles, and I’m the CSO of Humane Genomics, a biotech company focused on developing synthetic viruses as personalized therapeutics. You may not recall, but we met briefly at ASV 2018 at the University of Maryland. I enjoyed your discussion and thoughts on synthetic vaccinology.
Related to this, my company and I came up with a proposal for a COVID-19 vaccine. We aim to develop vesicular stomatitis virus (VSV) engineered with the spike glycoprotein of SARS-CoV-2. You can read more about it in the attached slide deck, or on our blog here and here. Of note, we received SARS-CoV-2 gene fragments today and plan to complete whole-genome assembly by Friday, bringing the design and build of vaccine candidates to 10 days.
I know you are currently collaborating with Moderna on their mRNA vaccine, but I would love to get your feedback on our vaccine proposal and learn more about how we can collaborate with government or advance our testing capabilities.
It would be great if we could setup a brief call to discuss.
Best regards,
Chad

---
Chad Moles, CSO @ Humane Genomics
(M) (b) (6); (W) humanegenomics.com

<COVID19 Vaccine 20200326.pdf>
Barney

Sent from my iPhone

On Mar 26, 2020, at 10:11 AM, Narpala, Sandeep (NIH/VRC) wrote:

Thank you.

Best,
Sandeep

Good morning,

Attaching the things in yellow. You can find the (b) (4), (b) (5) in an email that I sent already or Olubukola can share it here. I have been up all night so I am going to sleep and thus will not be replying to emails until tomorrow.

--
Kizzmekia S. Corbett, PhD
Senior Research Fellow | Scientific Lead
Good Morning Kizzie, Catherine and Olu,

Gentle reminder about the request below. Thank you.

Best,
Sandeep
Best,
Sandeep

From: "Corbett, Kizzmekia (NIH/VRC) [E]" <(b)(6)>
Date: Wednesday, March 25, 2020 at 3:05 PM
To: "Narpala, Sandeep (NIH/VRC) [C]" <(b)(6)>
Subject: Re: Status of (b)(4), (b)(5) Assay... Please Comment

--
Kizzmekia S. Corbett, PhD
Senior Research Fellow | Scientific Lead
Coronavirus Vaccines & Immunopathogenesis (coVip) Team
Viral Pathogenesis Laboratory | Vaccine Research Center
National Institutes of Allergy and Infectious Diseases
National Institutes of Health

Building 40 Room 2608
40 Convent Drive
Bethesda MD 20892

Laboratory: (b)(6)
Personal: (b)(6)
Fax: (301) 480-2771

From: "Narpala, Sandeep (NIH/VRC) [C]" <(b)(6)>
Date: Wednesday, March 25, 2020 at 2:11 PM
To: Kizzmekia Corbett <(b)(6)>
Subject: RE: Status of (b)(4), (b)(5) Assay... Please Comment

Hello Kizzie,

Thanks for putting together the shipment. Can you please fill out the information for (b)(4), (b)(5) in the table below and send it back to me? (b)(4), (b)(5)

Thanks.

Best,
Sandeep
How much do you need? I’m about to pack them up...

---

Kizzmekia S. Corbett, PhD  
Senior Research Fellow | Scientific Lead  
Coronavirus Vaccines & Immunopathogenesis (cOViP) Team  
Viral Pathogenesis Laboratory | Vaccine Research Center  
National Institutes of Allergy and Infectious Diseases  
National Institutes of Health  

Building 40 Room 2608  
40 Convent Drive  
Bethesda MD 20892  

Laboratory: (b)(6)  
Personal: (b)(6)  
Fax: (301) 480-2771

Hello Kizzie and Sarah,

Can you please provide the info for the (b)(4), (b)(5) today. I’m working on (b)(4), (b)(5) today. I’m working on (b)(4), (b)(5) today. I’m working on (b)(4), (b)(5) today. I’m working on (b)(4), (b)(5) today.

Best,  
Sandeep
If I can get to the 4th floor in the am at 10, I’m happy to do that. Maybe someone who is there can swap places with me... Catherine or lingshu, can you provide guidance of who will be in your lab at 10am tomorrow?

Sent from the mobile device of:
Kizzmekia S. Corbett, PhD
Senior Research Fellow
covip Scientific Lead
VRC | NIAID | NIH

---

Hello Kizzie and Catherine,

See response from XJ regarding

Best,
Sandeep
I will come and pick them up at 10AM tomorrow to pack in the box. Thanks Sarah.

--

Kizzmekia S. Corbett, PhD
Senior Research Fellow | Scientific Lead
Coronavirus Vaccines & Immunopathogenesis (coVip) Team
Viral Pathogenesis Laboratory | Vaccine Research Center
National Institutes of Allergy and Infectious Diseases
National Institutes of Health

Building 40 Room 2608
40 Convent Drive
Bethesda MD 20892
Laboratory: [b][c][b] Personal: [b][c][b]
Fax: (301) 480-2771
To: "Andrews, Sarah (NIH/VRC) [E]" , "Kanekiyo, Masaru (NIH/VRC) [E]" , "Narpala, Sandeep (NIH/VRC) [C]" , "McDermott, Adrian (NIH/VRC) [E]"
Cc: "Liu, Catherine (NIH/VRC) [C]"
Subject: Re: Status of (b)(4), (b)(5) Assay... Please Comment

Catherine Liu will be packing the box.

--
Kizzmekia S. Corbett, PhD
Senior Research Fellow | Scientific Lead
Coronavirus Vaccines & Immunopathogenesis (coVip) Team
Viral Pathogenesis Laboratory | Vaccine Research Center
National Institutes of Allergy and Infectious Diseases
National Institutes of Health

Building 40 Room 2608
40 Convent Drive
Bethesda MD 20892
Laboratory: (b)(6)
Personal: (b)(6)
Fax: (301) 480-2771

From: "Andrews, Sarah (NIH/VRC) [E]"
Date: Tuesday, March 24, 2020 at 10:27 AM
To: "Kanekiyo, Masaru (NIH/VRC) [E]" , "Narpala, Sandeep (NIH/VRC) [C]" , "McDermott, Adrian (NIH/VRC) [E]"
Cc: Kizzmekia Corbett
Subject: Re: Status of (b)(4), (b)(5) Assay... Please Comment

Let me know when and where I should have these (b)(4), (b)(5) today. I’ll need 30-40mins to get them as I’m at home.

Sarah

From: "Kanekiyo, Masaru (NIH/VRC) [E]"
Date: Tuesday, March 24, 2020 at 10:06 AM
To: "Andrews, Sarah (NIH/VRC) [E]" , "Narpala, Sandeep (NIH/VRC) [C]" , "McDermott, Adrian (NIH/VRC) [E]"
Cc: "Corbett, Kizzmekia (NIH/VRC) [E]" <(b)(6)>
Subject: Re: Status of (b)(4), (b)(5) Assay... Please Comment

Thank you, Sarah. I think we want (b)(4), (b)(5)

Masaru

From: Sarah Andrews <(b)(6)>
Date: Tuesday, March 24, 2020 at 10:03 AM
To: "Narpala, Sandeep (NIH/VRC) [C]" <(b)(6)>, "Kanekiyo, Masaru (NIH/VRC) [E]" <(b)(6)>, "McDermott, Adrian (NIH/VRC) [E]" 
Cc: Kizzmekia Corbett <(b)(6)>
Subject: Re: Status of (b)(4), (b)(5) Assay... Please Comment

I can get ahold of (b)(4), (b)(5) today for:

Sarah

From: "Narpala, Sandeep (NIH/VRC) [C]" <(b)(6)>
Date: Tuesday, March 24, 2020 at 10:00 AM
To: "Kanekiyo, Masaru (NIH/VRC) [E]" <(b)(6)>, "McDermott, Adrian (NIH/VRC) [E]" 
Cc: "Corbett, Kizzmekia (NIH/VRC) [E]" <(b)(6)>, "Andrews, Sarah (NIH/VRC) [E]" 
Subject: Re: Status of (b)(4), (b)(5) Assay... Please Comment

Masaru and Sarah,

Just to confirm, with both of you combined, (b)(4), (b)(5)
I will reach out to Azad for (b)(4), (b)(5) and Wei for (b)(4), (b)(5)

Best,
Sandeep

From: Kanekiyo, Masaru (NIH/VRC) [E] (b)(6)
Sent: Tuesday, March 24, 2020 9:56 AM
To: McDermott, Adrian (NIH/VRC) [E] (b)(6)>
Cc: Corbett, Kizzmekia (NIH/VRC) [E] (b)(6); Andrews, Sarah (NIH/VRC) [E] (b)(6); Narpala, Sandeep (NIH/VRC) [C] (b)(6)
Subject: Re: Status of (b)(4), (b)(5) Assay... Please Comment

We cannot get into the second floor today. It’s not possible unfortunately.

Masaru

From: "McDermott, Adrian (NIH/VRC) [E]" (b)(6)
Date: Tuesday, March 24, 2020 at 9:53 AM
To: "Kanekiyo, Masaru (NIH/VRC) [E]" (b)(6)>
Cc: Kizzmekia Corbett (b)(6); Sarah Andrews (b)(6); "Narpala, Sandeep (NIH/VRC) [C]" (b)(6)
Subject: Re: Status of (b)(4), (b)(5) Assay... Please Comment

(b)(4), (b)(5) Sorry but being pushy to get this going ASAP. Once we have this we can start to chat about (b)(4), (b)(5)

Sent from my iPhone

On Mar 24, 2020, at 9:48 AM, Kanekiyo, Masaru (NIH/VRC) [E] (b)(6) wrote:

I need Becky to send (b)(4), (b)(5) Probably can ship on Wednesday via fedex.

Masaru

From: Kizzmekia Corbett (b)(6)
Date: Tuesday, March 24, 2020 at 9:39 AM
To: Sarah Andrews (b)(6); "McDermott, Adrian (NIH/VRC) [E]" (b)(6); "Narpala, Sandeep (NIH/VRC) [C]" (b)(6)
Cc: "Kanekiyo, Masaru (NIH/VRC) [E]" (b)(6)
Subject: Re: Status of (b)(4), (b)(5) Assay... Please Comment

We are only looking for the following (b)(4), (b)(5) and Sandeep will advise on (b)(4). That said, I think (b)(4), (b)(5)
From: "Andrews, Sarah (NIH/VRC) [E]" (b) (6)>
Date: Tuesday, March 24, 2020 at 9:37 AM
To: "McDermott, Adrian (NIH/VRC) [E]" (b) (6)> , "Narpala, Sandeep (NIH/VRC) [C]" (b) (6)>
Cc: Kizzmekia Corbett (b) (6)>, "Kanekiyo, Masaru (NIH/VRC) [E]" (b) (6)>
Subject: Re: Status of (b) (4), (b) (5) Assay... Please Comment

Are you looking for any (b) (4), (b) (5) I could get ahold of today if you want it sent today.

Sarah

From: "McDermott, Adrian (NIH/VRC) [E]" (b) (6)>
Date: Tuesday, March 24, 2020 at 9:04 AM
To: "Narpala, Sandeep (NIH/VRC) [C]" (b) (6)>
Cc: "Corbett, Kizzmekia (NIH/VRC) [E]" (b) (6)>, "Andrews, Sarah (NIH/VRC) [E]" (b) (6)>, "Kanekiyo, Masaru (NIH/VRC) [E]"
Subject: Re: Status of (b) (4), (b) (5) Assay... Please Comment

Thanks Kizzie and Sandeep - we can also ask Sarah A (b) (4), (b) (5)

Kizzie, if you are sending reagents today to (b) (4), (b) (5)
On Mar 24, 2020, at 8:45 AM, Narpala, Sandeep (NIH/VRC) [C] wrote:

Hello Kizzie,

Thanks for the email. I will follow up with Masaru and others for the remaining (b) (4), (b) (5) after checking with them.

Will get back to you about the preferred way of sending the (b) (4), (b) (5).

Best,
Sandeep

From: "Corbett, Kizzmekia (NIH/VRC) [E]"
Date: Tuesday, March 24, 2020 at 7:09:13 AM
To: "Narpala, Sandeep (NIH/VRC) [C]", "McDermott, Adrian (NIH/VRC) [E]"
Subject: Re: Status of (b) (4), (b) (5) Assay... Please Comment

Good morning Sandeep & Adrian,

I have only heard about the (b) (4), (b) (5) Also Sandeep, please tell me how you would prefer the shipment (b) (4), (b) (5)
From: "Narpala, Sandeep (NIH/VRC) [C]" <(b)(6)>
Date: Friday, March 20, 2020 at 6:42 PM
To: Kizzmekia Corbett <(b)(6)>, "McDermott, Adrian (NIH/VRC) [E]" <(b)(6)>
Cc: "Kanekiyo, Masaru (NIH/VRC) [E]" <(b)(6)>, "Bok, Karin (NIH/VRC) [E]" <(b)(6)>, "Ruckwardt, Tracy (NIH/VRC) [E]" <(b)(6)>, Barney Graham <(b)(6)>, "Taylor, Alison (NIH/VRC) [C]" <(b)(6)>, "Stein, Judy (NIH/VRC) [C]" <(b)(6)>, "O'Connell, Sarah (NIH/VRC) [C]" <(b)(6)>, "Shi, Wei (NIH/VRC) [E]" <(b)(6)>, Wing-Pui Kong <(b)(6)>, "Kumar, Azad (NIH/VRC) [E]" <(b)(6)>
Subject: Re: Status of (b)(4), (b)(5) Assay... Please Comment

Hello Kizzie,

If you prefer

Alternatively, you can send

Best,
Sandeep

From: Corbett, Kizzmekia (NIH/VRC) [E] <(b)(6)>
Sent: Friday, March 20, 2020 6:25 PM
To: McDermott, Adrian (NIH/VRC) [E] <(b)(6)>
Cc: Kanekiyo, Masaru (NIH/VRC) [E] <(b)(6)>; Bok, Karin (NIH/VRC) [E] <(b)(6)>; Ruckwardt, Tracy (NIH/VRC) [E] <(b)(6)>
Narpala, Sandeep
Subject: Re: Status of (b) (4), (b) (5) Assay... Please Comment

No need for the (b) (4), (b) (5)- we got that.
If you have (b) (4), (b) (5) and folks can carry on with other COV stuff.
Adrian

Sent from my iPhone

On Mar 20, 2020, at 2:28 PM, Corbett, Kizzmekia (NIH/VRC) [E] wrote:

Hi all, if your name in beside the following (b) (4), (b) please send me in a separate email the availability of
I believe that Tracy is recruiting in Azad for (b)(4). (b)(5) here.

--

Kizzmekia S. Corbett, PhD
Senior Research Fellow | Scientific Lead
Coronavirus Vaccines & Immunopathogenesis (coVip) Team
Viral Pathogenesis Laboratory | Vaccine Research Center
National Institutes of Allergy and Infectious Diseases
National Institutes of Health

Building 40 Room 2608
40 Convent Drive
Bethesda MD 20892

Fax: (301) 480-2771

From: "McDermott, Adrian (NIH/VRC) [E]" <(b)(6)>
Date: Friday, March 20, 2020 at 2:22 PM
To: Kizzmekia Corbett (b)(6), "Kanekiyo, Masaru (NIH/VRC) [E]" (b)(6), "Bok, Karin (NIH/VRC) [E]" (b)(6), "Ruckwardt, Tracy (NIH/VRC) [E]" (b)(6), "Narpara, Sandeep (NIH/VRC) [C]" (b)(6), "Taylor, Alison (NIH/VRC) [C]" (b)(6), "Stein, Judy (NIH/VRC) [C]" (b)(6), "O'Connell, Sarah (NIH/VRC) [C]" (b)(6)
Cc: Barney Graham (b)(6), "Taylor, Alison (NIH/VRC) [C]" (b)(6)

Subject: Re: (b)(4), (b)(5) status?

OK – Kizzie you can discuss with Sarah et al at the lab

Still need to know availability of the (b)(4), (b)(5)
From: "Corbett, Kizzmekia (NIH/VRC) [E]" 
To: "McDermott, Adrian (NIH/VRC) [E]", "Kanekiyo, Masaru (NIH/VRC) [E]", "Bok, Karin (NIH/VRC) [E]", "Ruckwardt, Tracy (NIH/VRC) [E]", "Narpala, Sandeep (NIH/VRC) [C]", Barney Graham, "Taylor, Alison (NIH/VRC) [C]", "Stein, Judy (NIH/VRC) [C]", "O'Connell, Sarah (NIH/VRC) [C]" 
Cc: 
Subject: Re: status?

List as I see it below

--

Kizzmekia S. Corbett, PhD
Senior Research Fellow | Scientific Lead
Coronavirus Vaccines & Immunopathogenesis (coVip) Team
Viral Pathogenesis Laboratory | Vaccine Research Center
National Institutes of Allergy and Infectious Diseases
National Institutes of Health

Building 40 Room 2608
40 Convent Drive
Bethesda MD 20892
Laboratory: (b)(6)
Personal: (b)(6)
Fax: (301) 480-2771

From: "McDermott, Adrian (NIH/VRC) [E]" <(b)(6)>
To: "Kanekiyo, Masaru (NIH/VRC) [E]" <(b)(6)>, "Bok, Karin (NIH/VRC) [E]" <(b)(6)>
"Ruckwardt, Tracy (NIH/VRC) [E]" <(b)(6)>
"Narpala, Sandeep (NIH/VRC) [C]" <(b)(6)>, Barney Graham, "Taylor, Alison (NIH/VRC) [C]" <(b)(6)>, "Stein, Judy (NIH/VRC) [C]" <(b)(6)>, "O'Connell, Sarah (NIH/VRC) [C]" <(b)(6)>

NIH-001141
Barney, Masaru and Kizzie,

Absolutely.....That is not the final.....copy errors in there from a spreadsheet I was given and like the

We need to decide ASAP!!

Any particular reason for having

Just my thoughts.
Heard you on the meeting this morning....

We can do this quickly

Thanks
Thanks John,

And we need to coordinate with Tracy because she is developing a

Barney

Sent from my iPhone

On Feb 14, 2020, at 8:54 AM, Mascola, John (NIH/VRC) [E] wrote:

Hi Maryam,

We want to take a systematic approach here.
Please make a short PP slide deck of your project and current data – borrowing from draft Figs.

We want to decide soon – so we can craft your thesis and paper.

Best,

John

NIH-001154
Hi Jason,

I hope you are well and understand you must be very busy with SARS-CoV-2 work.

Thank you very much.

Sincerely,
Maryam
<VRC317_Public_Clones.xlsx>
Thanks Ofer.

BG
Thanks for all and have a good weekend,

Ofer

Ofer Levy MD, PhD
Staff Physician & Principal Investigator
Director, Precision Vaccines Program
Division of Infectious Diseases
Boston Children’s Hospital
Professor, Harvard Medical School
Associate Member, Broad Institute
Office: (b) (6)
Cell: (b) (6)
E-mail: (b) (6)
Twitter: @PrecVaccines, @EPICVaccines
facebook.com/PrecisionVaccines
linkedin.com/company/PrecisionVaccines

Dear [Redacted]

I am happy to answer any questions.
Dear Ofer,

I have attached the [b] attachment. Thanks very much.

Kind regards,

From: Graham, Barney (NIH/VRC) [E] <---------
b (6)
Sent: Wednesday, February 5, 2020 6:28 PM
To: Ofer Levy <---------
b (6)
Cc: Dowling, David <---------
b (6); Diane Vo (Levy) <---------
b (6); Borriello, Francesco <---------
b (6); Bok, Karin (NIH/VRC) [E] <---------
b (6); Morabito, Kaitlyn (NIH/VRC) [E] <---------
b (6); Corbett, Kizzmekia (NIH/VRC) [E] <---------
b (6)
Subject: Re: -----------------------------
[EXTERNAL]

Hi Ofer,

I have connected you to [b] connection.

NIH-001158
On Feb 3, 2020, at 7:28 PM, Levy, Ofer <b>(b)(6)</b> wrote:

Hi Barney

Thanks for your reply.

We are hoping to start working <b>(b)(4)</b>

All the best,

Ofer

---

Ofer Levy MD, PhD
Staff Physician & Principal Investigator
Director, Precision Vaccines Program
Division of Infectious Diseases
Boston Children’s Hospital
Professor, Harvard Medical School
Associate Member, Broad Institute
Office: <b>(b)(6)</b>
Cell: <b>(b)(6)</b>
E-mail: <b>(b)(6)</b>
Twitter: @PrecVaccines, @EPICVaccines
facebook.com/PrecisionVaccines
linkedin.com/company/PrecisionVaccines

From: Barney Graham <b>(b)(6)>
Date: Saturday, February 1, 2020 at 7:18 AM
Hi Ofer,

Sorry for delay. I have not been able to keep up. Our primary agenda is to get the mRNA into the clinic and get the preclinical and diagnostics going.

Barney

Sent from my iPhone

On Jan 29, 2020, at 11:20 PM, Levy, Ofer wrote:

Hi Barney,

Hope all is well.

In this context, do you have any suggestions?

Thanks for all and hope to speak soon,

Ofer

Ofer Levy MD, PhD
Staff Physician & Principal Investigator
Director, Precision Vaccines Program
Division of Infectious Diseases
Boston Children's Hospital
Professor, Harvard Medical School
Associate Member, Broad Institute
Office: (b)(6)
Cell: (b)(6)
E-mail: (b)(6)
Twitter: @PrecVaccines, @EPICVaccines
facebook.com/PrecisionVaccines
linkedin.com/company/PrecisionVaccines

<Scren Shot 2016-02-03 at 1.39.14 PM[3][194].png>
BTW, my flight home tomorrow lands about 4pm so I could get on the Moderna call shortly after.

BG

Sent from my iPhone

On Jan 16, 2020, at 5:24 PM, Corbett, Kizzmekia (NIH/VRC) [E] wrote:

Hi Dr. Graham,

Thanks,

Sent from the mobile device of:
Kizzmekia S. Corbett, PhD
Senior Research Fellow
NIH | NIAID | VRC
From: "Corbett, Kizzmekia (NIH/VRC) [E]" (b)(6)
Date: Thursday, January 16, 2020 at 6:32:20 PM
To: "Morabito, Kaitlyn (NIHNRC) [E]" (b)(6)
Subject: Re: Wuhan CoV - (b)(4)

Hi Kaitlyn,

... (content deleted for redaction)

--

Kizzmekia S. Corbett, PhD
Senior Research Fellow
National Institutes of Health
National Institutes of Allergy and Infectious Diseases
Vaccine Research Center
Viral Pathogenesis Laboratory

Building 40 Room 2608
40 Convent Drive
Bethesda MD 20892
Laboratory: (b)(6)
Personal: (b)(6)
Fax: (301) 480-2771

From: Kaitlyn Morabito (b)(6)
Date: Tuesday, January 14, 2020 at 8:24 PM
To: Barney Graham (b)(6), Hamilton Bennett (b)(6), Sunny Himansu (b)(6), "Stein, Judy (NIH/VRC) [C]" (b)(6), Andrea Carfi (b)(6), Kizzmekia Corbett (b)(6)
Cc: Andrea Carfi (b)(6)
Subject: Re: Wuhan CoV - (b)(4)

NIH-001163
Hamilton and all,

Please let us know if you have any questions. Barney is on travel at the end of the week, but it looks like he may have some time early on Tuesday Morning before 10 if you are available.

Best,
Kaitlyn

From: Barney Graham
Date: Tuesday, January 14, 2020 at 4:01 PM
To: Hamilton Bennett, Morabito, Kaitlyn (NIH/VRC) [E]
Cc: Andrea Carfi, Kizzmekia Corbett
Subject: RE: Wuhan CoV -

I asked that the so hopefully tonight.

BG

From: Hamilton Bennett
Sent: Tuesday, January 14, 2020 3:56 PM
Hi Kaitlyn and Barney,

Would you be able to provide an update on

I suggest we regroup the end of the week if that works for you. Andrea and I are both available at 4pm on Thursday and Friday.

Cheers,

Hamilton Bennett
Associate Director, Vaccine Access and Partnerships | Moderna
Tel: (b) (6) | Cell: (b) (6) | modernatx.com
information by persons or entities other than the intended addressee(s) is prohibited. If you have received this message in error and are not the intended addressee, please notify the sender immediately and delete this message and any attachments from your system without reading or disclosing them. If you are not the intended addressee, be advised that any use of the information in this message and any attachment is prohibited and may be unlawful, and you must not copy this message or attachment or disclose the contents to any other person.

<2019-nCoV S-2P & SARS Sequence for Moderna_20200116.docx>
FYI. What do you think?

Barney
Sent from my iPhone

On Mar 19, 2020, at 12:19 PM, (b)(4), (b)(6) wrote:

Barney,

(b)(4)

From: Graham, Barney (NIH/VRC) [E] (b)(6)
Sent: Thursday, March 19, 2020 12:03 PM
To: (b)(4), (b)(6)
Subject: [EXTERNAL] RE: (b)(4)

EXTERNAL : Real sender is (b)(6)

BG

From: (b)(4), (b)(6)
Sent: Thursday, March 19, 2020 11:59 AM
To: Graham, Barney (NIH/VRC) [E] (b)(6)
Subject: RE: (b)(4)

From: Graham, Barney (NIH/VRC) [E] (b)(6)
Sent: Thursday, March 19, 2020 11:52 AM
To: (b)(4), (b)(6)
Subject: [EXTERNAL] Re: (b)(4)

EXTERNAL : Real sender is (b)(6)
On Mar 19, 2020, at 11:47 AM, (b) (4) wrote:

Thank you for your quick reply. All the best,

From: Graham, Barney (NIH/VRC) [E] <(b) (6)>
Sent: Thursday, March 19, 2020 11:38 AM
To: (b) (4), (b) (6)
Subject: [EXTERNAL] Re: (b) (4)

EXTERNAL: Real sender is (b) (6)
Hi Trevor. Nice to hear from you.

Do you have

Best wishes and take care,

Barney

Sent from my iPhone

> On Apr 16, 2020, at 7:43 PM, Douglas, Trevor wrote:
> Hi Barney
> I hope you are well in these challenging times. I’m sure this is a very busy time for you - hopefully it is also a productive time for your vaccine work ...against SARS-CoV-2!
> Look forward to hearing from you.
> Regards,
> Trevor Douglas
> Earl Blough Professor of Chemistry
> Department of Chemistry
> Indiana University
> 800 E. Kirkwood Avenue
> Bloomington, IN 47405
Hi Brandon,

Would be glad to talk. Today is a little full, but by tomorrow evening there should be time.

Would you prefer early or late in the day.

Barney

Hi Barney,

I hope all is good! I was on a call with John Mascola this morning, 

If you might have a few minutes to connect, let me know and would love to chat.

In any case, stay well and look forward to catching up soon!

Best,

Brandon
Brandon DeKosky, Ph.D.
Assistant Professor
Department of Chemical & Petroleum Engineering
Department of Pharmaceutical Chemistry
Kansas Vaccine Institute
The University of Kansas
2095 Simons Biosciences Research Labs, Rm 136B
Lawrence, KS 66044

tel: 

http://www.dekoskylab.org
Thanks Darrel,

I think all the experiences I had and people I met at KUSM-Wichita and Vanderbilt prepared me well for what we are going through now. Hopefully some of these early efforts will work.

Best wishes and take care,

Barney

---

Dear Barney,

I saw the article in Science where you were working on a coronavirus vaccine. That prompted me to drop you a line to say "Thanks" for all the great work you do. I appreciate all the time and effort you have put in to understanding viruses and how to protect the public from them. Who knew back in those days at KUSM-Wichita and Vanderbilt that we'd be in the middle of a pandemic?

I trust you are doing well.

Stay safe! We need good physician-scientists like you!

Best regards,

Darrel

Darrel L. Ellis, M.D.
Professor
Department of Dermatology
Vanderbilt University and Nashville VA Medical Centers
Nashville, TN
Hi Andrea.

Barney

Sent from my iPhone

On Apr 20, 2020, at 10:54 PM, Andrea Carfi <andreacarfi@nih.gov> wrote:

Hi Barney,
A month ago you mention some

Best,

Andrea

Please consider the environment before printing this email

Confidentiality notice and disclaimer: The information in this message and any attachments is intended for the exclusive use of the addressee(s), is confidential and may be privileged or otherwise protected from disclosure. Any review, retransmission, dissemination or other use of, or taking of any action in reliance upon, of any such information by persons or entities other than the intended addressee(s) is prohibited. If you have received this message in error and are not the intended addressee, please notify the sender immediately and delete this message and any attachments from your system without reading or disclosing them. If you are not the intended addressee, be advised that any use of the information in this message and any attachment is prohibited and may be unlawful, and you must not copy this message or attachment or disclose the contents to any other person.
FYI. This would only be 30 minutes from now. Not much time to respond.

BG

Sent from my iPhone

Begin forwarded message:

From: "Flattery, Siobhan" <Siobhan.Flattery@FOXNEWS.COM>
Date: March 11, 2020 at 3:20:59 PM EDT
To: "Graham, Barney (NIH/VRC) [E]"
Subject: Fox News Radio Interview Request

Hello Dr. Graham,

My name is Siobhan Flattery I work at FOX News Radio in New York. I’m reaching out to see if you are available today to join our syndicated daily news show and popular podcast the FOX News Rundown to discuss the latest on the coronavirus, the WHO declaring the coronavirus outbreak a pandemic?

This will be a 10-15 minute, pre-taped, audio interview with our host Jessica Rosenthal. We can do interviews today until 5:30PM ET via skype (preferably) or landline. Please no cellphone.

The FOX News Rundown is a news-based weekday syndicated morning show and podcast hosted by FOX News Radio anchors, that offers a deep dive into the major and controversial stories of the day. We strive to offer contrasting perspectives that may not be heard elsewhere while going far beyond the basic headlines. Each weekday The FOX News Rundown features insight from top newsmakers, along with FOX News reporters and contributors, plus a daily commentary on a significant issue of the day.

(You can listen to previous podcasts by visiting: https://radio.foxnews.com/podcast/fox-news-rundown/)

Please email – or call me at the number below if you have any further questions or to confirm a time for today’s interview.

Thank you in advance,
Siobhan
Siobhan {Sha-von} Flattery
FOX News Radio Podcast Coordinator
1211 Avenue of the Americas | New York, NY 10036
Phone: 212 301 5840

This message and its attachments may contain legally privileged or confidential information. It is intended solely for the named addressee. If you are not the addressee indicated in this message (or responsible for delivery of the message to the addressee), you may not copy or deliver this message or its attachments to anyone. Rather, you should permanently delete this message and its attachments and kindly notify the sender by reply e-mail. Any content of this message and its attachments that does not relate to the official business of Fox News or Fox Business must not be taken to have been sent or endorsed by either of them. No representation is made that this email or its attachments are without defect.
3:30 or 5:00 PM tomorrow could work for short calls.

Barney

HI Barney-
Unfortunately, I will be in an IRB meeting at 4:30 and . Are you available anytime tomorrow?

Thank you.
Christine

Christine Grady
Chief, Department of Bioethics
NIH Clinical Center

I could talk at 4:30 today and also give you some text to use if needed.

Barney

Sent from my iPhone
On Apr 8, 2020, at 1:33 PM, Grady, Christine (NIH/CC/BEP) [E] (b)(6) wrote:

Thank you so much, Barney.
we would appreciate your perspective on these few questions:

If it would be easier to talk by phone, please let me know.
Thank you so much.

Christine

Christine Grady
Chief, Department of Bioethics
NIH Clinical Center

From: Graham, Barney (NIH/VRC) [E] <(b)(6)>
Sent: Tuesday, April 7, 2020 11:21 AM
To: Grady, Christine (NIH/CC/BEP) [E] (b)(6)>
Cc: Danis, Marion (NIH/CC/BEP) [E] (b)(6)>
Subject: Re: seeking your assistance

Hi Christine,

I’m a clinician and virologist, (b)(5) I’m glad to help if given those caveats you think I can.

Take care,

Barney

Sent from my iPhone
HI Barney-

I hope you and yours are well and staying safe.

I am writing to see if you or someone else from VRC could help us.

Thank you very much,
Christine
Having been on a call with Stanley Perlman (one of the co-authors) reviewing enhanced disease concepts, I am less concerned about this paper.

Barney

Interesting that Skip Virgin also sent me this article late yesterday so I have read through it this am. Its really quite a decent article, in my opinion, and it appears to show that in the adoptive transfer studies of antibodies low doses of what is defined as neutralizing antibodies is associated with more cellular infiltration in the lower lungs which they almost solely characterize as macrophages but there is no staining of other cells e.g. T cells NK B cells etc. So I think the data on the “causal issues” that its some alteration in macrophage dysfunction is less cogent not because the data are wrong but because other explanations are also quite plausible just not outlined or looked for.
Thanks Emily .. kept me home in social mitigation for an hour this am!!

There are several studies in NHP, one I’ve seen showing a potential safety signal in NHP. I think others were equivocal or negative.

Anti-spike IgG causes severe acute lung injury by skewing macrophage responses during acute SARS-CoV infection -
Liu et al., 2019
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6478436/

• In SARS-CoV/macaque models, vaccine-induced S-specific immunity resulted in severe ALI in SARS-CoV infected Chinese macaques.

Emily Erbelding, M.D., M.P.H.
Director, Division of Microbiology and Infectious Diseases
NIAID/NIH
5601 Fishers Lane
Rockville, MD 20852
Tel: 

From: Corey MD, Larry [b] (6)
Sent: Wednesday, March 11, 2020 9:25 PM
To: Mascola, John (NIH/VRC) [E] [b] (6)
Cc: Erbelding, Emily (NIH/NIAID) [E] [b] (6); Dieffenbach, Carl (NIH/NIAID) [E] [b] (6); Graham, Barney (NIH/VRC) [E] [b] (6)
Subject: Re: Reuters: As pressure for coronavirus vaccine mounts, scientists debate risks of accelerated testing

It is a very well done article. Informative. Nice quotes from you Emily. Complicated
We’re any SARS vaccine trials done in NHPs.? Uses the same receptor. Guess I need to look up the assays used in articles reporting coronavirus enhancement

Sent from my iPhone

On Mar 11, 2020, at 5:38 PM, Mascola, John (NIH/VRC) [E] (b) (6) wrote:

The issue of enhancement already getting press. See below.

John

From: Folkers, Greg (NIH/NIAID) [E] (b) (6)
Sent: Wednesday, March 11, 2020 11:00 AM
Subject: Reuters: As pressure for coronavirus vaccine mounts, scientists debate risks of accelerated testing

March 11, 2020 / 7:07 AM / Updated 4 hours ago

As pressure for coronavirus vaccine mounts, scientists debate risks of accelerated testing

Julie Steenhuysen
10 Min Read

CHICAGO (Reuters) - Drugmakers are working as quickly as possible to develop a vaccine to combat the rapidly spreading coronavirus that has infected more than 100,000 people worldwide.
FILE PHOTO: Nurse Jeff Gates processes a patient sample at a drive-through testing clinic for coronavirus, flu and RSV, currently by appointment for employees at UW Medical Center Northwest in Seattle, Washington, U.S. March 9, 2020. REUTERS/Lindsey Wasson

Behind the scenes, scientists and medical experts are concerned that rushing a vaccine could end up worsening the infection in some patients rather than preventing it.

Studies have suggested that coronavirus vaccines carry the risk of what is known as vaccine enhancement, where instead of protecting against infection, the vaccine can actually make the disease worse when a vaccinated person is infected with the virus. The mechanism that causes that risk is not
fully understood and is one of the stumbling blocks that has prevented the successful development of a coronavirus vaccine.

Normally, researchers would take months to test for the possibility of vaccine enhancement in animals. Given the urgency to stem the spread of the new coronavirus, some drugmakers are moving straight into small-scale human tests, without waiting for the completion of such animal tests.

“I understand the importance of accelerating timelines for vaccines in general, but from everything I know, this is not the vaccine to be doing it with,” Dr Peter Hotez, dean of the National School of Tropical Medicine at Baylor College of Medicine, told Reuters.

Hotez worked on development of a vaccine for SARS (Severe Acute Respiratory Syndrome), the coronavirus behind a major 2003 outbreak, and found that some vaccinated animals developed more severe disease compared with unvaccinated animals when they were exposed to the virus.

“There is a risk of immune enhancement,” said Hotez. “The way you reduce that risk is first you show it does not occur in laboratory animals.”

Hotez testified last week before the U.S. House Committee on Science, Space and Technology about the need for sustained funding for vaccine research. There remains no vaccine for any of the new coronaviruses that have caused outbreaks in the past 20 years.

At least for now, the world’s experts have concluded that accelerated testing is a risk worth taking. At a specially convened World Health Organization (WHO) meeting in mid-February, designed to coordinate a global response to the new coronavirus, scientists representing government-funded research organizations and drugmakers around the world agreed that the threat was so great that vaccine developers should move quickly into human trials, before animal testing is completed, four people who attended the meeting told Reuters.

“You want to have a vaccine as quickly as possible,” Dr Marie-Paule Kieny, former assistant director-general at the WHO, who co-chaired the meeting, told Reuters. “You have to balance this with the risk that you impose on a very small number of people, and do all you can do to mitigate this risk as much as possible.”

The conclusion of that meeting, which was not open to media, has not been officially publicized by the WHO. It does not reflect any official position adopted by the WHO, a United Nations body whose job it is to help shape global health policy.

Regulatory oversight of drugmakers and medical research is in the hands of national regulators. The most powerful of those, the U.S. Food and Drug Administration (FDA), has signaled that it is in agreement with the consensus and will not stand in the way of accelerated testing schedules.

“When responding to an urgent public health situation such as novel coronavirus, we intend to exercise regulatory flexibility and consider all data relevant to a certain vaccine platform,” FDA spokeswoman Stephanie Caccamo said in a statement. The agency had no comment specifically on animal testing for vaccine enhancement.

Coronavirus vaccine developers are still required to conduct routine animal testing to make sure the vaccine itself is not toxic and is likely to help the immune system respond to the virus.

SEATTLE RISK

Some 20 coronavirus vaccine candidates are being developed by research institutes and drugmakers including America’s Johnson & Johnson and France’s Sanofi SA. The U.S. government has earmarked more than $3 billion for coronavirus treatments and vaccines.

Biotechnology company Moderna Inc, which is working with the U.S.-funded National Institutes of Health (NIH), is the closest to human testing, announcing plans to start a trial with 45 people in Seattle this month.

Testing for the specific risk of vaccine enhancement in animals will proceed simultaneously with human trials, the NIH told Reuters, which it said should establish whether it is safe to expose larger numbers of people to the vaccine. Moderna did not respond to requests for comment.
The plan is consistent with the WHO consensus and FDA requirements, said Dr Emily Erbelding, director of the Division of Microbiology and Infectious Diseases of the National Institute of Allergy and Infectious Diseases (NIAID), part of the NIH. The trial is expected to take 14 months, a spokeswoman for the NIH said.

Dr Gregory Poland, a virologist and vaccine researcher with the Mayo Clinic in Rochester, Minnesota, expressed doubts about that approach. “This is important, but it has to be done in a way that reassures scientists and the public that these (vaccines) are not only efficacious, but safe,” he told Reuters. Hotez said he was surprised human trials were going ahead. “If there is immune enhancement in laboratory animals vaccinated with the Moderna vaccine, that’s a showstopper,” he said.

U.S. immunotherapy company Inovio Pharmaceuticals Inc, which is developing a coronavirus vaccine in collaboration with a Chinese company, also expects to start human clinical trials in 30 U.S. volunteers in April rather than wait for animal studies on vaccine enhancement.

“Unlike the community as a whole weighed that and said we don’t want to delay the clinical process. We’ve been encouraged to go as rapidly as possible into Phase 1 studies,” Inovio Chief Executive Joseph Kim told Reuters.

The company plans to start human safety trials shortly thereafter in China and South Korea - two countries that have been hit hard by the virus. Kim said he expects to have an answer to the question of vaccine enhancement at some point this year.

The Moderna/NIH trial is enrolling patients at the Kaiser Permanente Washington Health Research Institute in Seattle. The choice of location, made several weeks ago, could prove to be problematic.

To reduce the risk to volunteers, scientists at the WHO meeting recommended that drugmakers restrict early clinical trials to small groups of healthy people and conduct them in places where the virus is not spreading, according to Kieny, who now works at French research institute Inserm. That lowers the chances that people who get the vaccine could encounter the virus and trigger a more severe reaction.

Since the location was chosen, the Seattle metro area has emerged as the epicenter of infections in the United States. Washington state has reported 162 coronavirus infections and 22 deaths, out of a total of 755 infections and 26 deaths in the country as of Tuesday, according to a tally by Johns Hopkins University.

Nevertheless, Moderna and the NIH plan to go ahead.

“We think there is no reason to have to change the site. If you change it, there might be community transmission in another site over the next couple of weeks,” Erbelding said. “Any risk of that to participants is very small. It would be manageable as the trial progresses. People are being observed very, very carefully.”

**EARLY WARNING SIGNS**

Tragic lessons from other vaccines and prior work on coronaviruses have raised some warning flags for developers.

The best-known example occurred in a U.S. trial in the 1960s of a vaccine created by the NIH and licensed to Pfizer Inc to fight respiratory syncytial virus (RSV), which causes pneumonia in infants. The vast majority of babies who received the vaccine developed more severe disease, and two toddlers died.

A more recent example occurred in the Philippines, where some 800,000 children were vaccinated with Sanofi’s dengue vaccine, Dengvaxia. Only afterward did the company learn that it could increase the risk of more severe disease in a small percentage of individuals.

Research, including that conducted by Hotez, has shown that coronaviruses in particular have the potential to produce this kind of response. But testing for the risk of vaccine enhancement is time-consuming because it requires scientists to breed mice that are genetically altered to respond to the virus like humans. Work on these and other animal models is just getting under way in several laboratories around the world.
Moderna, Inovio and several other vaccine developers are not waiting for that process to be completed and are planning to launch human trials in record time for a virus that was only discovered in December.

Both Moderna and Inovio say their vaccines are likely to have a lower risk of vaccine enhancement because they are made using newer technology that focuses on specific genes on the outer ‘spike’ portion of the virus. Coronavirus vaccines that caused vaccine enhancement were typically made using an inactivated version of the entire virus. Neither company has produced a licensed vaccine to date. J&J said it is developing animal models to test for vaccine enhancement and hopes to have a vaccine candidate ready for human trials in October. A Sanofi spokeswoman said the company will examine this risk before testing the vaccine in clinical trials.

“People know how traumatic the RSV experience was,” said Dr Johan Van Hoof, global head of Janssen Vaccines, J&J’s vaccine unit. “When you see signals in animals like this, we should not ignore them.”

Reporting by Julie Steenhuyzen in Chicago; Additional reporting by Michael Erman in New York; Editing by Michele Gershberg and Bill Rigby

Disclaimer: Any third-party material in this email has been shared for internal use under fair use provisions of U.S. copyright law, without further verification of its accuracy/veracity. It does not necessarily represent my views nor those of NIAID, NIH, HHS, or the U.S. government.
We spoke to WSJ on Saturday. Went well but won’t know until we see the article.

I’m not going to have time for the Toronto reporter. Could they watch the Science Facebook post?

Barney

Sent from my iPhone

On Mar 23, 2020, at 10:44 AM, Hiatt, Nissa (NIH/VRC) wrote:

Hi Barney and Kizzmekia,

A reporter from the Toronto Star would like to talk to an expert today by phone or email. His questions are about the development of NIAID’s COVID-19 vaccine, and the clinical trial. I know this is a really quick turnaround so OCGR did offer to draft written response for you to review or decline if everyone is busy. They also offered to send for clearance, if one of you has time today to talk on the phone - quicker since this is a print request. Please let me know your preferences!

Were you able to connect with Peter Loftus from the WSJ or will you talk to him today?

Thanks in advance!

Nissa

Nissa Hiatt
Communications
Vaccine Research Center, NIAID, NIH
40 Convent Drive, Bldg 40, Room 1100
Bethesda, MD 20892
Cell: (b)(6)
Office: (b)(6)
Thanks for your email. I am under the impression that with our closed campus and inability to hire or bring on special volunteers that this may not be possible. My PI, Dr. Barney Graham, can comment otherwise if apt.

Thanks tremendously for contacting us.

--
Kizzmekia S. Corbett, PhD
Senior Research Fellow | Scientific Lead
Coronavirus Vaccines & Immunopathogenesis (coVip) Team
Viral Pathogenesis Laboratory | Vaccine Research Center
National Institutes of Allergy and Infectious Diseases
National Institutes of Health

Building 40 Room 2608
40 Convent Drive
Bethesda MD 20892
Laboratory: (b)(6)
Personal: (b)(6)
Fax: (301) 480-2771
Dear Kizzmekia,

My name is (b) (6) I wanted to send my warmest congratulations on the work you been doing and say how proud we are of how you've been representing. Keep it up!

I also am writing to get your help and guidance. My colleagues (scientists) and I have been thinking of ways to assist in this crisis. I received the message (below) from a good friend and researcher in Boston. Do you know if NIAID would accept this type of information? Or, perhaps the communications department?

Certainly, there are many aspects of federal operations and response that make it different from the state level. But, I was wondering if NIH would accept this voluntary information of people with relevant skills that want to help, and if there was a particular department that would handle it. There may be other initiatives you're of that may be more suitable. Any guidance would be appreciated.

Be Well,

(b) (6)

National Science Foundation
10400A (b) (6)

--------------------------------------------

Hey I made a google form and more than 6,000 people responded and now I need to get it into the hands of decision makers. Know anyone at NSF who is trying to get their hands on this info? We have a few states using the database, but nothing yet at the federal level.

https://tinyurl.com/COVID19SciVolunteers
https://tinyurl.com/COVID19SciVolunteersFAQ
All right. I could also take a call around 7am.

Barney

Sent from my iPhone

On Jan 26, 2020, at 9:26 PM, Bryan White <bryan.white@nih/vrc> wrote:

Neil, thank you for the introduction. Barney, I’ve heard your name more than a dozen times from Neil when he was developing the IPD and subsequently at Icosavax. I know you’ve been a great collaborator.

Let me check with timing and Rob, he is likely in New York but could be London or Hong Kong.

I’ll be back soon,

Bryan

Sent from my iPhone

On Jan 26, 2020, at 7:23 PM, Neil King <neil.king@nih/vrc> wrote:

What time zone is he in? My best time would be driving to the airport tomorrow about 2pm EST.

BG

Sent from my iPhone

On Jan 26, 2020, at 7:23 PM, Neil King <neil.king@nih/vrc> wrote:
Hi Barney,

Bryan White (cc'd), who I'm sure you'll meet someday, is on the IPD's Advisory Board and has a friend who has major financial operations in Hong Kong and would like to learn more about the Wuhan Coronavirus (see note below). I know you are crazy busy dealing with this right now, but is there any chance you (or someone in your group) might be able to speak with Rob?

Thanks,
Neil

On Sun, Jan 26, 2020 at 4:06 PM Bryan White wrote:
What about someone at the VRC say Barney Graham. They have a large operation in Hong Kong and elsewhere. I suspect he has some basic questions like whether dusk masks are effective and whether you can diagnose it.

On Jan 26, 2020, at 2:03 PM, Neil King wrote:

Hi Bryan,

I'd be happy to, but I am not the most knowledgeable person. Depends on how hardcore he wants to get. I can definitely tell him generally how viruses work and how they spread, and about vaccines. But I am not a hardcore Coronavirus expert.

Happy to help,
Neil

On Sun, Jan 26, 2020, 3:54 PM Bryan White wrote:
Neil would you have 30-60 minutes to speak to Rob? He is the leader of one of the leading financial firms in the world.

Begin forwarded message:

From: rob granieri
Date: January 26, 2020 at 8:38:16 AM HST
To: Bryan White
Subject: coronavirus

Hi Bryan.
At Jane Street we're trying to learn more about the coronavirus and how it might spread, and it occurred to me that you may have a suggestion for how to get a more scientific view on what's happening. We're of course happy to pay someone as a consultant if they can give us some advice.

Thanks
As I noted earlier, goes through Julie first. I’m sure they will be willing to adjust.

Barney

Sent from my iPhone

On Apr 23, 2020, at 11:40 AM, Corbett, Kizzmekia (NIH/VRC) [E] wrote:

Dr. Graham, can you bring in Martin? And speak about the I am not familiar with anyone in the clinic.

--

Kizzmekia S. Corbett, PhD
Senior Research Fellow | Scientific Lead
Coronavirus Vaccines & Immunopathogenesis (coVip) Team
Viral Pathogenesis Laboratory | Vaccine Research Center
National Institutes of Allergy and Infectious Diseases
National Institutes of Health

Building 40 Room 2608
40 Convent Drive
Bethesda MD 20892
Laboratory: (b) (6)
Personal: (b) (6)
Fax: (301) 480-2771

From: Kaitlyn Morabito (b) (6)
Date: Thursday, April 23, 2020 at 11:31 AM
To: Barney Graham (b) (6), Kizzmekia Corbett (b) (6)
Subject: Re: (b) (6)

Yes, for (b) (5).
Did Julie agree to this yet? The clinic is stretched pretty thin right now with COVID-19,

You can email Julie Ledgerwood who might send you to Alicia Wide or Ingelise Gordon.

Barney

Who do we discuss [b][5] with? [b][5] I think.

---

Kizzmekia S. Corbett, PhD
Senior Research Fellow | Scientific Lead
Coronavirus Vaccines & Immunopathogenesis (coVip) Team
Viral Pathogenesis Laboratory | Vaccine Research Center
National Institutes of Allergy and Infectious Diseases
National Institutes of Health

Building 40 Room 2608
40 Convent Drive
Bethesda MD 20892
Laboratory: [b][6]
Personal: [b][6]
Fax: (301) 480-2771
Works for me. I just will need to coordinate with my Zoom meeting schedule.

-----
John Misasi, M.D.
Staff Clinician
NIH/NIAID
Vaccine Research Center
Biodefense Research Section
Rm 2510
40 Convent Drive
Bethesda, MD 20892

-----
I agree with that schedule if feasible for all.

Barney

Good afternoon Dr. Misasi, Thanks for following up.
--

Kizzmekia S. Corbett, PhD
Senior Research Fellow | Scientific Lead
Coronavirus Vaccines & Immunopathogenesis (coVip) Team
Viral Pathogenesis Laboratory | Vaccine Research Center
National Institutes of Allergy and Infectious Diseases
National Institutes of Health

Building 40 Room 2608
40 Convent Drive
Bethesda MD 20892

Laboratory: (b) (6)
Personal: (b) (6)
Fax: (301) 480-2771

---

From: "Misasi, John (NIH/VRC) [E]" (b) (6)
Date: Friday, April 17, 2020 at 4:47 PM
To: Kizzmekia Corbett (b) (6)
Subject: (b) (6)

Hey,

(b) (6)

John

-----

John Misasi, M.D.
Staff Clinician
NIH/NIAID

NIH-001203
Thanks Brian.

BG

Sent from my iPhone

On Mar 20, 2020, at 5:50 PM, Fisher, Brian (NIH/VRC) [E] wrote:

Yea, I have been getting a lot of similar emails from vendors. Ignore them. I'm not sure of their phishing or not but I won't risk it.

B.

Sent from my iPhone

Begin forwarded message:

From: Josh Croteau <jcroteau@biolegend.com>
Date: March 20, 2020 at 5:10:43 PM EDT
To: "Graham, Barney (NIH/VRC) [E]" (b)(6)
Subject: Receiving shipments during COVID-19 situation
Reply-To: jcroteau@biolegend.com
Hi Barney,

I hope you are doing well.

To make sure we are getting reagents to you during this time, can you please answer the questions below?

1) Is your lab still operational?
2) Is your institution/company shut down and not receiving shipments?
3) Do you need your shipments sent to a different address because your receiving is not available?
4) If yes to #2 and #3 (your receiving is closed), and, you still require shipment to your lab, please follow these actions:

Provide detailed receiving instructions to both BioLegend and to the shipping carrier (e.g. FedEx):

If you opt in to use a non-standard delivery address, let me know and I’ll send you a liability and delivery waiver to sign.

If you have any questions, please let me know. Thank you!

Best wishes,
Josh

Josh Croteau, Ph.D.
Technical Application Scientist II
Mobile: (b)(6)

BioLegend
8999 BioLegend Way
San Diego, CA 92121
United States
https://www.biolegend.com

If you would like to stop receiving notification emails, click here.
Yes, please. Sorry for delayed answer. Not keeping up.

BG

Hi Barney,
If it is okay with you, I can send them a SLA today.
Thanks
Judy

Should we cc the whole group, as we initiate?

FYI. We should probably send some to India.

BG
Hi, Gray and all.

Thank you so much for the rapid response. We had ordered reagents for the CDC protocol and got them today from local suppliers and will set up the assay. Apparently there is an issue with one of the negative controls provided by CDC—that is useful to know and we will be careful with specificity.

As advised by Sara we will initiate the paperwork for the transfer immediately.

Barney, thank you so much. Yes, absolutely, we have both

Thanks again and regards,

Cherry

On Wed, 19 Feb 2020, 22:48 Handley, Gray (NIH/NIAID) [E], wrote:

Dear Cherry,

As you will have seen in the note from Dr. Sara Woodson, you can access these reagents from the BEI repository which is supported by NIAID. I noted that the question of a need for export license is being resolved. Hopefully this will be settled quickly. We will be happy to facilitate this access if you run into any challenges we can help with.

In addition, Dr. Barney Graham has offered to provide a small amount of He suggests that THSTI should be able to re-create the CDC PCR.
Please feel free to reach out directly to Barney, Sara or Kimberly Stemple (JoJo) if you have any questions.

Also please let me know if I can be of further assistance.

Gray

F. Gray Handley
Associate Director for International Research Affairs
National Institute of Allergy and Infectious Diseases
National Institute of Health
U.S. Department of Health and Human Services

Tel: (b)(6) 5601 Fishers Lane, Room E50
Fax: 301 480 2954 Bethesda, MD 20892-9802

Disclaimer:
The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. National Institute of Allergy and Infectious Diseases shall not accept liability for any statements made that are sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: G Kang (b)(6)
Sent: Tuesday, February 18, 2020 9:28 PM
To: Handley, Gray [NIH/NIAID] [E] --------------------c (b;;-s-)=(6)
Dr. Renu Swarup (b)(6) _>; ALKA SHARMA (b)(6); Guruprasad Medigeshi (b)(6); Milan Surjit (b)(6); Tripti Shrivastava (b)(6)
Subject: Request for SARS-CoV2

Dear Gray,

I spoke with Dr. Renu Swarup yesterday and she asked me to reach out directly for reagents that we need for diagnostics for SARS-CoV-2 or COVID-19.

BEI has the virus grown by the CDC listed in its catalog as SARS-Related Coronavirus 2, Isolate USA-WA1/2020, NR-52281.

Is there someone who could help us with the process of getting the virus to India? If helpful, at THSTI, we have been through the agreements with NIAID for the dengue strains from Steve Whitehead. Have not received them yet, but I believe the paperwork is complete.

I know you will be very busy, but if (b)(6) or you could connect us to the right people, we can follow up.

Thanks and regards,

Cherry
Gagandeep Kang / Executive Director
Translational Health Science and Technology Institute
(An autonomous institute of the Dept of Biotechnology, Govt Of India)
NCR Biotech Science Cluster,
3rd Milestone, Faridabad-Gurgaon Expressway
PO Box #4, Faridabad, Haryana-120001
Phone: (b) (6)
Website: www.thsti.res.in
Hi Barney,

Masaru and I are being asked by people what to do, and did discuss. Some cases are easy, and others are more difficult.

Not sure if you are having this problem, but I’m being booted out of the GoTo with an indication that a server may be down or overloaded. Not sure if it is a local problem (connection can be difficult sometimes in my neighborhood), or due to the NIH VPN bandwidth as traffic picks up (hopefully not). Maybe I’ll have better success with a phone call next time.

Tracy
Adrian,
I agree with the idea of

I will keep you updated.

Masaru

** Sent from Outlook mobile app

Hi Adrian,

Thank you for sharing your thoughts. Everything you say makes sense, so we need to find the right balance. I hope that by trusting each other and being considerate of each other we will be able to get through this.

We will be reconsidering our situation on a day by day basis.

Barney

Sent from my iPhone

On Mar 16, 2020, at 5:28 PM, Creanga, Adrian (NIH/VRC) [E] wrote:
Dear Barney and Masaru,

Sorry to bother you with this.

I wrote this message with the best intentions and knowledge I have. I maybe wrong and miss some critical information. I apologize for my confusion.

Thank you for your understanding!

Adrian
Subject: RE: Lab attendance and duties

FYI

How to kill CoV

https://www.medrxiv.org/content/10.1101/2020.03.09.20033217v2

MERS CoV on environmental services — Attached

First trial participant enrolled!

Dear Lab,

You recently received emails from Dr. Collins and the VRC leadership about what to do during the looming coronavirus pandemic. Let me say a little more about what I expect from you. These are interesting and unprecedented times at least within my lifetime. We have to balance our own personal health against the public health and the functioning of the lab against the functioning of our families. I want this to work out well for everyone and for everyone to stay well. However, it is likely that some of us will eventually encounter the new coronavirus and if that happens we need to be mindful of our own health and the health of others around us. If you think you have been exposed or are developing symptoms, please stay home and contact me and seek medical help if needed.

Although we have been granted liberal telework options, it is important that we find a way to continue the coronavirus work. If you have any questions about what to do, please talk to the head of your group, either Tracy, Masaru, or Kizzy. You are also welcome to talk with me if needed.

I will be working off site for the next few days, and will be back in the office on Thursday. I am available by email and phone if needed.

Best wishes,

Barney

**************************************
Barney S. Graham, MD, PhD
Senior Investigator
Deputy Director, Vaccine Research Center
Chief, Viral Pathogenesis Laboratory
National Institute of Allergy and Infectious Diseases, NIH
40 Convent Drive, MSC 3017
The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. National Institute of Allergy and Infectious Diseases shall not accept liability for any statements made that are sender's own and not expressly made on behalf of the NIAID by one of its representatives.
Barney

Sent from my iPhone

On Apr 28, 2020, at 7:48 PM, Mascola, John (NIH/VRC) [E] <(b)(6)> wrote:

I wonder (b)(5) . . . ?

From: Sarah Anderson (b)(6) Sent: Tuesday, April 28, 2020 7:27 PM To: Mulach, Barbara (NIH/NIAID) [E] (b)(6) Cc: Collins, Francis (NIH/OD) [E] (b)(6>; Mascola, John (NIH/VRC) [E] (b)(6) Erbelding, Emily (NIH/NIAID) [E] (b)(6) Subject: RE: NIH Moderna Vaccine Candidate Questions - Reply Required

Dear Ms. Mulach,

Thank you very much for the courtesy of a prompt and detailed response. It’s always appreciated to get reply when engaging with our Government and these are not normal times so Thank You for address my questions/concerns.

I appreciate the detail in your reply with the mention of a number of vaccine candidates you indicate as under evaluation. I’m not sure what the status is of those evaluations so I’d like to focus on current singular US taxpayer investment of $434 Million in the Moderna mRNA-1273 vaccine. You’ve indicated NIAID may have some indication of immune response on mice from a prior NIAID funded trial (still in Phase 1 as I seen reported by Moderna) with sufficient mice protection. This seems like pretty early days baseline data for the huge ($434M) investment for a single option vaccine candidate – my risky “single shot at the goal” concern.

My concern has only been compounded today after seeing the just published results of another US Biotech company (Inovio Pharmaceuticals) for their MERS vaccine in Phase 2. You may be familiar with Inovio as they are the only other US company currently in human trials in the US (and Korea) for a Covid-19 vaccine. Today, Inovio published their MERS INO-4700 (GLS-5300) DNA vaccine demonstrates 100%
binding and 92% neutralizing antibody responses against MERS. Inovio's CoV-INO-4800 DNA vaccine for COVID-19 currently in Phase 1 trial utilizes identical strategy targeting Spike protein and CELLECTRA intradermal delivery. This is a STRONG human response to their MERS vaccine — not mice indications like the Moderna trial so heavily funded by the US Government/NIAID.


Inovio's Covid vaccine is currently receiving funding from the Gates Foundation and CEPI. S. Korean government is funding a trial in S. Korea as well. My question for you and the NIH Director is why isn't the US Government also supporting this vaccine candidate that has shown such superior results?? This cannot be a one horse race for a vaccine and it also cannot be a 'who has NIAID worked with in the past' race for a vaccine. The stakes are too high for citizens live and our economy not to support ALL the options that have already shown solid results.

When can I expect to see my Government invest in a company that is already showing strong MERS Covid related results - like Inovio - to help drive for the vaccine we so critically need?? I look forward to seeing another prompt response.

Thank you in advance,
Sarah Anderson
Kirkland WA

---

From: Mulach, Barbara (NIH/NIAID)  
Sent: Friday, April 24, 2020 9:05 AM  
To:  
Subject: RE: NIH Moderna Vaccine Candidate Questions - Reply Required

Dear Ms. Anderson,

Thank you for your recent message to staff at the National Institute of Allergy and Infectious Diseases. As the Director of the Office of Scientific Coordination and Program Operations in the Division of Microbiology and Infectious Diseases, I’m pleased to respond.

We very much appreciate you reaching out to NIAID with your questions about vaccines for COVID-19. NIAID scientists collaborated with the biotechnology company Moderna, Inc., to develop the investigational mRNA vaccine (mRNA-1273). The vaccine is currently being evaluated in a Phase 1 clinical trial: https://clinicaltrials.gov/ct2/show/NCT04233461. The trial is being funded by NIAID and conducted through the Institute's Infectious Diseases Clinical Research Consortium (IDCRC), a clinical trials network that encompasses NIAID’s Vaccine and Treatment Evaluation Units (VTEUs). The Coalition for Epidemic Preparedness Innovations (CEPI) supported the manufacturing of the vaccine candidate for the Phase 1 clinical trial. The immunogenicity of mRNA-1273 has been tested in mice and was found to be similar to that of an mRNA vaccine previously tested for MERS (another coronavirus). That level of immune response was sufficient to protect mice from MERS CoV infection.
In addition to the mRNA vaccine, NIAID is evaluating multiple candidate vaccines for COVID-19, many of which utilize different technologies. For example, scientists at NIAID's Rocky Mountain Laboratories are working on a chimpanzee adenovirus-vectored vaccine, while NIAID-funded investigators are evaluating whether vaccines developed for SARS may be adapted for evaluation against SARS-CoV-2. For more information about NIAID's research on coronaviruses, including SARS-CoV-2, please see: https://www.niaid.nih.gov/diseases-conditions/coronaviruses.

NIAID also is working in partnership across government agencies to prioritize the preclinical and clinical testing for numerous other candidate vaccines. This includes collaboration with the Biomedical Advanced Research and Development Authority (BARDA), part of the Health and Human Services Office of the Assistant Secretary for Preparedness and Response (ASPR). BARDA is rapidly establishing partnerships to advance the development of vaccines, therapeutics, diagnostics, and other technologies for COVID-19. Information on those efforts can be found at: https://www.medicalcountermeasures.gov/app/barda/coronavirus/COVID19.aspx. Finally, the National Institutes of Health and the Foundation for the National Institutes recently announced the Accelerating COVID-19 Therapeutic Interventions and Vaccines (ACTIV) partnership. ACTIV brings together more than a dozen leading biopharmaceutical companies, ASPR, the Centers for Disease Control and Prevention, the U.S. Food and Drug Administration and the European Medicines Agency to prioritize vaccine and drug candidates, streamline clinical trials, coordinate regulatory processes and leverage assets among all partners in response to the COVID-19 pandemic. For more information on ACTIV, including the partnership focus areas, please see: https://www.nih.gov/news-events/news-releases/nih-launch-public-private-partnership-speed-covid-19-vaccine-treatment-options.

Thank you again for contacting NIAID.
Sincerely,
Barbara Mulach

Barbara L. Mulach, Ph.D.
Director, Office of Scientific Coordination and Program Operations
Division Small Business Coordinator
Division of Microbiology and Infectious Diseases
5601 Fishers Lane, Room 7G61
Rockville, MD 20892-9826 (For deliveries, use 20852)
Phone: (b) (6)
E-mail: (b) (6)
National Institute of Allergy and Infectious Diseases
National Institutes of Health, DHHS
Disclaimer:
The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage device. National Institute of Allergy and Infectious Diseases shall not accept liability for any statements made that are sender's own and not expressly made on behalf of the NIAID by one of its representatives.

Get Help Turning Your Discoveries into New Diagnostics, Vaccines, and Therapeutics:
Dr Erbelding, Dr. Mascola and Dr Corbett,

Let me start by thanking each you for your service and your efforts to fast track a COVID19 vaccine – something we desperately need. THANK YOU!

As many Americans, I’m closely following those vaccine efforts to educate myself on the science and the taxpayer monies invested. Your NIH/Moderna mRNA vaccine has been heavily funded by the US Government (NIH & BARDA) and has a human trial underway. There’s a lot of hope (especially by the NIH as it’s the only COVID19 vaccine candidate currently NIH funded) for this vaccine. I share that hope as well so when I read this article with its detailed unbiased review of the vaccine and they raise a number of critical questions, I am disturbed both Moderna & the NIH failed to comment. Why is there no comment from the NIH on something this important?


Additional questions all Americans need answered are: Why is the NIH investing in a single COVID19 vaccine candidate? What is the science that supports the ‘one shot at the goal’ approach? Were there animal studies on this vaccine prior to human trials? If not, why not? There are a number of other vaccine candidates either in human trial now or ready to proceed now – why is the NIH using taxpayer funding only on a single COVID19 candidate – the Moderna vaccine?

This isn’t a private investment decision as the NIH is responsible for the health of the American People and it’s never been needed more than at this moment. I expect the NIH to respond to the questions raised by the above article, to be transparent to the American People about your vaccine efforts and to practice good science which doesn’t prescribe to a ‘one shot at the goal’ approach. There are too many lives at risk for the NIH to do otherwise and those lives are responsible for your funding.

As a taxpayer providing your funding, I would appreciate (and actually expect) a reply to my questions. Thank you in advance.
Regards,
Sarah Anderson
Kirkland WA
Here is Word version.

Thanks,

BG

-----Original Message-----
From: Gemma Alderton <galderton@science-int.co.uk>
Sent: Monday, April 20, 2020 5:48 AM
To: Graham, Barney (NIH/VRC) [E] <galde1t01@science-int.co.uk>
Cc: awynn@aaas.org
Subject: RE: Preparing a Perspective for Science ID abb8923

Thanks Barney! I have uploaded it and will get it to expedited review now. I hope to have feedback for you by the end of the week/early next week. Could you send me the Word (or equivalent) version when you have a moment.

Best wishes,
Gemma

Gemma K. Alderton, PhD
Senior Editor, Science
AAAS Science International, Inc.
E: galderton@science-int.co.uk
www.sciencemag.org
cts.sciencemag.org

Follow me on Twitter: @AldertonBiol

-----Original Message-----
From: Graham, Barney (NIH/VRC) [E] <galde1t01@science-int.co.uk>
Sent: 18 April 2020 19:10
To: Gemma Alderton <galderton@science-int.co.uk>
Cc: awynn@aaas.org
Subject: RE: Preparing a Perspective for Science ID abb8923

Here is the referenced perspective. I wasn't able to switch it with the unreferenced version on the web site. Do you have to provide a permission for that?

Best wishes,
Barney
-----Original Message-----
From: Gemma Alderton <galderton@science-int.co.uk>
Sent: Friday, April 17, 2020 8:14 AM
To: Graham, Barney (NIH/VRC) [E] (b) (6)>
Cc: awynn@aaas.org
Subject: RE: Preparing a Perspective for Science ID abb8923

Great, thank you.

Best wishes,
Gemma

Gemma K. Alderton, PhD
Senior Editor, Science
AAAS Science International, Inc.
E: galderton@science-int.co.uk
www.sciencemag.org
cts.sciencemag.org

Follow me on Twitter: @AldertonBiol

-----Original Message-----
From: Graham, Barney (NIH/VRC) [E] (b) (6)>
Sent: 17 April 2020 12:11
To: Gemma Alderton <galderton@science-int.co.uk>
Cc: awynn@aaas.org
Subject: RE: Preparing a Perspective for Science ID abb8923

OK. Glad to add references.

Barney

-----Original Message-----
From: Gemma Alderton <galderton@science-int.co.uk>
Sent: Friday, April 17, 2020 2:18 AM
To: Graham, Barney (NIH/VRC) [E] (b) (6)>
Cc: awynn@aaas.org
Subject: RE: Preparing a Perspective for Science ID abb8923

Dear Barney,

Many thanks for your Perspective - this is great. I'm afraid that I do need you to add references please, a maximum of 15. I know this means picking references out of many, but I cannot proceed with your submission without them. Did you want to add a figure? You do not have to, but it might be helpful to explain some of the concepts in your piece. If you could send me a referenced version, I will get this to expedited review.

Thanks and best wishes,
Gemma

Gemma K. Alderton, PhD
Dear Dr. Alderton,

I have attached the perspective here and I will also go into the website and submit later tonight.

This short perspective could have had dozens of references, but I have added none. Let me know if you would like me to add references, but it would be hard to add one without all the rest.

Thank you for the opportunity to publish by perspectives.

Best wishes and take care,

Barney

Barney S. Graham, MD, PhD
Senior Investigator
Deputy Director, Vaccine Research Center Chief, Viral Pathogenesis Laboratory National Institute of Allergy and Infectious Diseases, NIH
40 Convent Drive, MSC 3017
Bldg 40, Room 2502
Bethesda, MD 20892-3017
Phone: 301 594-8468
URL: https://www.niaid.nih.gov/research/barney-graham-md-phd

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. National Institute of Allergy and Infectious Diseases shall not accept liability for any statements made that are sender's own and not expressly made on behalf of the NIAID by one of its representatives.

-----Original Message-----
From: Gemma Alderton <galderton@science-int.co.uk>
Sent: Tuesday, April 14, 2020 9:25 AM
To: Graham, Barney (NIH/VRC) [E] <(b) (6)>
Cc: awynn@aaas.org
Subject: RE: Preparing a Perspective for Science ID abb8923

-----Original Message-----
From: Gemma Alderton <galderton@science-int.co.uk>
Sent: Tuesday, April 14, 2020 9:25 AM
To: Graham, Barney (NIH/VRC) [E] <(b) (6)>
Cc: awynn@aaas.org
Subject: RE: Preparing a Perspective for Science ID abb8923
Great, thank you!

Gemma K. Alderton, PhD
Senior Editor, Science

AAAS Science International, Inc.
E: galderton@science-int.co.uk
www.sciencemag.org
cts.sciencemag.org

Follow me on Twitter: @AldertonBiol

-----Original Message-----
From: Graham, Barney (NIH/VRC) [E]
Sent: 14 April 2020 14:23
To: Gemma Alderton <galderton@science-int.co.uk>
Cc: awynn@aaas.org
Subject: Re: Preparing a Perspective for Science ID abb8923

I should be able to send tomorrow.

Barney

Sent from my iPhone

> On Apr 14, 2020, at 7:42 AM, Gemma Alderton <galderton@science-int.co.uk> wrote:
> Dear Barney,
> I hope all is well with you. I just want to check that you are going to be able to submit your Perspective tomorrow? Please let me know how you are getting on and if you need more time.
> Best wishes,
> Gemma
> Gemma K. Alderton, PhD
> Senior Editor, Science
> AAAS Science International, Inc.
> E: galderton@science-int.co.uk
> www.sciencemag.org
> cts.sciencemag.org
> Follow me on Twitter: @AldertonBiol
> -----Original Message-----
> From: Anita Wynn <science_editors@aaas.org>
> Sent: 25 March 2020 12:26
> To: awynn@aaas.org; Gemma Alderton <galderton@science-int.co.uk>
> Subject: Preparing a Perspective for Science ID abb8923
> 25-Mar-2020
>
> Dear Dr. Graham,
>
> Manuscript number: abb8923
>
> Thank you for agreeing to write a Perspective for Science on SARS-CoV-2 vaccine development.
>
> Your paper is due at Science by 15-Apr-2020. If for some reason you find that you will not be able to meet this deadline, please let us know as soon as possible.
>
> When you are ready to submit your paper, please log in to your account at our Manuscript Submission and Information Portal https://cts.sciencemag.org. This solicited manuscript will appear on your task list. You can access the manuscript record by clicking on the Action button to the right of the paper in your task list. Navigate between tabs to complete your manuscript record and upload documents.
>
> I look forward to receiving your manuscript. Please let me know if I can be of assistance.
>
> Sincerely,
>
> Gemma Alderton, Ph.D.
> Senior Editor
> galderton@science-int.co.uk
Barney

Sent from my iPhone

On Mar 31, 2020, at 7:37 AM, Corbett, Kizzmekia (NIH/VRC) [E] wrote:
Things that I am aware of:

1. 
2. 
3. 
4. 

Have a good day.

--

Kizzmekia S. Corbett, PhD
Senior Research Fellow | Scientific Lead
Coronavirus Vaccines & Immunopathogenesis (coVip) Team
Viral Pathogenesis Laboratory | Vaccine Research Center
National Institutes of Allergy and Infectious Diseases
National Institutes of Health

Building 40 Room 2608
40 Convent Drive
Bethesda MD 20892
Laboratory: (b)(6)
Personal: (b)(6)
Fax: (301) 480-2771

From: Barney Graham (b)(6)
Date: Tuesday, March 31, 2020 at 7:29 AM
To: Kizzmekia Corbett (b)(6)
Subject: Re: Sending mRNA-1273 mouse serum to UNC for Nanoluc PRNT assays

Let's review this in more detail. It seems to me that

BG

Sent from my iPhone

On Mar 31, 2020, at 7:21 AM, Corbett, Kizzmekia (NIH/VRC) [E] (b)(6)> wrote:

Dr. Graham,

(b)(4) this is what I have been doing.
Barney Graham wrote:

"On Mar 31, 2020, at 6:56 AM, Stevens, Laura J [b][6] wrote:

Barney

Sent from my iPhone"
Hi Kizzy,

OK on everything else

NIH-001235
Hi all,

I am replying here with the following comments:

- Please provide the...

- Please provide...

at the VRC then shipped.

Thank you.

Sent from the mobile device of:
Kizzmekia S. Corbett, PhD
Senior Research Fellow
coVip Scientific Lead
VRC | NIAID | NIH

From: "Sunny Himansu" (b) (6)
Date: Monday, March 30, 2020 at 8:54:51 AM
To: "Chappell, Jim" (b) (6)
Cc: "Corbett, Kizzmekia (NIH/VRC) [E]" (b) (6), "Stevens, Laura J" (b) (6), "Hankins, Jody L" (b) (6), "Morabito, Kaitlyn (NIH/VRC) [E]" (b) (6), "Alvarado, Gabriela (NIH/VRC) [C]" (b) (6), "Stein, Judy (NIH/VRC) [C]" (b) (6), "Denison, Mark" (b) (6), "Martinez, David Rafael" (b) (6), "Graham, Barney (NIH/VRC) [E]" (b) (6), "Baric, Ralph S" (b) (6)
Subject: RE: Sending mRNA-1273 mouse serum to UNC for Nanoluc PRNT assays
All,

Here is a signed copy of the agreement. Also, I was told to communicate that I only signed once since am the duly authorized signatory for Moderna.

Sunny

From: Chappell, Jim (b)(6)
Sent: Sunday, March 29, 2020 9:59 AM
To: Sunny Himansu (b)(6)
Cc: Corbett, Kizzmekia (NIH/VRC) [El (b)(6); Stevens, Laura J (b)(6); Hankins, Jody L (b)(6)
Subject: RE: Sending mRNA-1273 mouse serum to UNC for Nanoluc PRNT assays

Thank you, Sunny.

In addition to Kizzy, I am copying lab member Laura Stevens and Vanderbilt tech. transfer officer, Dr. Jody Hankins.

Jim

From: Sunny Himansu (b)(6)
Sent: Sunday, March 29, 2020 6:25 AM
To: Martinez, David Rafael (b)(6)
Cc: Graham, Barney (NIH/VRC) (b)(6); Alvarado, Gabriela (NIH/VRC) [C] (b)(6); Morabito, Kaitlyn (NIH/VRC) [E] (b)(6); Baric, Ralph (b)(6); Chappell, Jim (b)(6); Denison, Mark (b)(6); Stein, Judy (NIH/VRC) [C] (b)(6)
Subject: RE: Sending mRNA-1273 mouse serum to UNC for Nanoluc PRNT assays

Hi Kizzy,

Please go ahead and ship the samples on Monday. We have accepted the draft agreement as is so I will and share that shortly

Sunny

From: Corbett, Kizzmekia (NIH/VRC) [E] (b)(6)
Sent: Saturday, March 28, 2020 3:25 AM
To: Martinez, David Rafael (b)(6)
Cc: Sunny Himansu (b)(6); Graham, Barney (NIH/VRC) [E] (b)(6); Alvarado, Gabriela (NIH/VRC) [C] (b)(6); Morabito, Kaitlyn (NIH/VRC) [E] (b)(6); Baric, Ralph (b)(6); Chappell, Jim (b)(6); Denison, Mark (b)(6); Stein, Judy (NIH/VRC) [C] (b)(6)
Subject: Sending mRNA-1273 mouse serum to UNC for Nanoluc PRNT assays

NIH-001237
Good morning Sunny,

If agreements are apt for each institution, I can ship these out on Monday. Please advise.

Sent from the mobile device of:
Kizzmekia S. Corbett, PhD
Senior Research Fellow
covip Scientific Lead
VRC | NIAID | NIH

From: "Martinez, David Rafael" (b)(6)
Date: Friday, March 27, 2020 at 12:21:49 PM
To: "Corbett, Kizzmekia (NIH/VRC) [E]" (b)(6)
Subject: shipping address

Hi Kizzy,

See below - thanks

VRC

David Martinez
135 Dauer Drive
3109 Michael Hooker Research Center
CHAPEL HILL, NC 27599
Please consider the environment before printing this email

Confidentiality notice and disclaimer: The information in this message and any attachments is intended for the exclusive use of the addressee(s), is confidential and may be privileged or otherwise protected from disclosure. Any review, retransmission, dissemination or other use of, or taking of any action in reliance upon, of any such information by persons or entities other than the intended addressee(s) is prohibited. If you have received this message in error and are not the intended addressee, please notify the sender immediately and delete this message and any attachments from your system without reading or disclosing them. If you are not the intended addressee, be advised that any use of the information in this message and any attachment is prohibited and may be unlawful, and you must not copy this message or attachment or disclose the contents to any other person.

[WARNING: This email came from an external source. Please treat this message with additional caution.]

[WARNING: This email came from an external source. Please treat this message with additional caution.]
I have answered the questions below.

Barney

**************************
Barney S. Graham, MD, PhD
Senior Investigator
Deputy Director, Vaccine Research Center
Chief, Viral Pathogenesis Laboratory
Vaccine Research Center, NIAID, NIH
40 Convent Drive, MSC 3017
Bldg 40, Room 2502
Bethesda, MD 20892-3017
Phone: (b)(6)
URL: https://www.niaid.nih.gov/research/barney-graham-md-phd

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. National Institute of Allergy and Infectious Diseases shall not accept liability for any statements made that are sender's own and not expressly made on behalf of the NIAID by one of its representatives.

Reporter: Eric Boodman
Organization: STAT
Phone #: (b)(6) eric.boodman@globe.com
Subject: Coronavirus, animal model used in testing Moderna candidate vaccine

1. My understanding is that wild type mice are not susceptible to Covid-19 virus. What has been modified in the mice that will be used in the next in vivo step to make them susceptible to the virus?

After the 2003 SARS outbreak transgenic mice were made that express the human ACE2 gene to make them susceptible to infection.

2) Do those mice exist already and to what extent do we know how susceptible they are to the virus and what sorts of disease they show?
As noted, those mice exist and had been previously shared with Chinese investigators who have shown the mice can be infected with SARS-CoV-2. Those mice in the U.S. are being bred so that the colony can be enlarged.

3) When will those optimized challenge models be ready?
Those mice will be available for experiments within the next few weeks.

4) Will there be efficacy results from testing mRNA-1273 in optimized challenge models before clinical testing begins in April, as Dr. Fauci has stated it will?
Safety and product integrity are the primary criteria for starting a Phase 1 trials and mRNA has now been used in several clinical trials and shown to be safe and well tolerated. The immunogenicity of mRNA-1273 has been tested in mice and is similar to that of MERS CoV mRNA that has been previously tested. That level of immune response was sufficient to protect mice from MERS CoV infection.

Eric’s piece on animal models from today: https://www.statnews.com/2020/03/05/coronavirus-labs-scramble-to-find-right-animals-for-covid-19-studies/

Anne A. Oplinger
Office of Communications
National Institute of Allergy and Infectious Diseases
National Institutes of Health
Bldg 31, Rm. 7A17D
Media Line: (301) 402-1663
General Line: (301) 594-3961

(b)(6)
Hi Jason,

See note below.

If possible and if there is bandwidth, could the VPP help with making more of this?

Barney

---

Hi John,

I talked with Dr. Graham about the potential of making a large batch given both of our labs' use and it being discontinued commercially. We may go in the direction of having this scaled at the VPP. Maybe you (and/or Olu and/or Rebecca) can comment on the amount you think we'd need moving forward across research activities.

Sent from the mobile device of:
Kizzmekia S. Corbett, PhD
Senior Research Fellow
coVip Scientific Lead
NIH | NIAID | VRC
That will be clarified at 11 by me.

BG

Sent from my iPhone

On Mar 30, 2020, at 9:23 AM, Corbett, Kizzmekia (NIH/VRC) [E] wrote:

Dr. Graham,
I think everyone

We need clarity.

--
Kizzmekia S. Corbett, PhD
Senior Research Fellow | Scientific Lead
Coronavirus Vaccines & Immunopathogenesis (coVip) Team
Viral Pathogenesis Laboratory | Vaccine Research Center
National Institutes of Allergy and Infectious Diseases
National Institutes of Health

Building 40 Room 2608
40 Convent Drive
Bethesda MD 20892
Laboratory: (b)(6)
Personal: (b)(6)
Fax: (301) 480-2771
I would like to use most of this time to discuss the [redacted].

I’m going to have some long days on Tues and Wed because I’m supposed to be attending the virtual SAGE meeting that starts at 4am each day.

Tracy, do we know the status of [redacted]?
Barney

*****************************************************
Barney S. Graham, MD, PhD
Senior Investigator
Deputy Director, Vaccine Research Center
Chief, Viral Pathogenesis Laboratory
National Institute of Allergy and Infectious Diseases, NIH
40 Convent Drive, MSC 3017
Bldg 40, Room 2502
Bethesda, MD 20892-3017
Phone: (b)(6)
URL: https://www.niaid.nih.gov/research/barney-graham-md-phd
The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. National Institute of Allergy and Infectious Diseases shall not accept liability for any statements made that are sender's own and not expressly made on behalf of the NIAID by one of its representatives.
See attachment.

BG

On Jan 23, 2020, at 10:55 AM, Graham, Barney (NIH/VRC) [E] <(b)(6)> wrote:

... (b)(5)

BG

OSLO, NORWAY. Jan 23, 2020 — CEPI, the Coalition for Epidemic Preparedness Innovations, today announced the initiation of three programmes to develop vaccines against the novel coronavirus, nCoV-2019.

The programmes will leverage rapid response platforms already supported by CEPI as well as a new partnership. The aim is to advance nCoV-2019 vaccine candidates into clinical testing as quickly as possible.

The nCoV-2019 vaccine development efforts will build on existing partnerships with Inovio (Nasdaq: INO) and The University of Queensland (located in Brisbane, Australia). In addition, CEPI today announces a new partnership with Moderna, Inc., (Nasdaq: MRNA) and the U.S. National Institute of Allergy and Infectious Diseases.

All of these are pioneering technologies designed to speed up the development of vaccines against emerging threats such as nCoV-2019.

Given the rapid global spread of the nCoV-2019 virus the world needs to act quickly and in unity to tackle this disease. Our intention with this work is to leverage our work on the MERS coronavirus and rapid response platforms to speed up vaccine development. There are no guarantees of success, but we hope this work could provide a significant and important step forward in developing a vaccine for this disease. Our aspiration with these technologies is to bring a new pathogen from gene sequence to clinical testing in 16 weeks – which is significantly shorter than where we are now.

Richard Hatchett
CEO of CEPI

The term “platform technology” broadly refers to systems that use the same basic components as a backbone but can be adapted for use against different pathogens as needed by inserting new genetic or protein sequences.

CEPI has moved with great urgency and in coordination with WHO, who is leading the development of a coordinated international response, to promote the development of new vaccines against the emerging threat of nCoV-2019. The novel coronavirus represents the first new epidemic disease of note to emerge since CEPI’s founding at Davos in 2017, with the express intent that it should be ready to respond to epidemics rapidly and effectively, wherever they emerge.

Inovio | DNA vaccine candidate against Middle East Respiratory Syndrome
CEPI announced a **partnering agreement**, worth up to US$56 million, with Inovio in April 2018, to advance DNA vaccine candidates against MERS and another of its priority diseases, Lassa fever, through to Phase 2.

Under the agreement, funding will support the development up to the end of Phase 2, providing clinical safety, immunological data, and the establishment of investigational stockpiles that will be ready for clinical efficacy trial testing during outbreaks.

The MERS DNA vaccine candidate is being developed using Inovio’s DNA Medicines platform to deliver optimised synthetic antigenic genes into cells, where they are translated into protein antigens that activate an individual’s immune system to generate robust targeted T cell and antibody responses.

Inovio’s immunotherapies function exclusively in vivo, and have generated an antigen-specific immune response against targeted diseases in all clinical trials to date.

Inovio is advancing its MERS vaccine candidate into Phase 2, in the Middle East where most MERS viral outbreaks have occurred, with the support of its collaborators: The Wistar Institute, Laval University, the NIH’s Rocky Mountain Laboratories, U.S. Army Medical Research Institute of Infectious Diseases (USAMRIID), VGXI/GeneOne Life Science and the International Vaccine Institute.

**University of Queensland | The molecular clamp platform**

CEPI entered a **partnering agreement** in January 2019, with University of Queensland, for up to US$ 10.6 million to develop a “molecular clamp” vaccine platform, a transformative technology that enables targeted and rapid vaccine production against multiple viral pathogens.

The technology works by synthesising viral surface proteins, which attach to host cells during infection, and “clamping” them into shape, making it easier for the immune system to recognise them as the correct antigen. This process requires the sequence of the viral protein which can then be determined from the viral genome. The synthetic antigen can then be purified and rapidly manufactured into a vaccine.

As part of their partnering agreement with CEPI, the University of Queensland will use their molecular-clamp vaccine platform to produce vaccines against known pathogens, including Middle East Respiratory Syndrome coronavirus (MERS-CoV) and will evaluate the safety and immune response of the Influenza and MERS-CoV candidates in a phase 1 clinical trial in humans.

**Moderna | mRNA vaccine platform**

Under the terms of the agreement with CEPI, Moderna will manufacture an mRNA vaccine against coronavirus, which will be funded by CEPI. Investigational New Drug-enabling studies will be conducted by the Vaccine Research Center (VRC) and a Phase 1 clinical study will be conducted in the 3 U.S. by the Division of Microbiology and Infectious Diseases (DMID). Both VRC and DMID are divisions of the National Institute of Allergy and Infectious Diseases (NIAID), which is an institute of the NIH.

---

**About the novel coronavirus**

Coronaviruses are a family of viruses that can lead to respiratory illness, including Middle East Respiratory Syndrome (MERS-CoV) and Severe Acute Respiratory Syndrome (SARS-CoV). Coronaviruses are transmitted between animals and people and can evolve into strains not previously identified in humans. On January 7, 2020, a novel coronavirus (2019-nCoV) was identified as the cause of pneumonia cases in Wuhan City, Hubei Province of China, and additional cases have been found in a growing number of countries.

**About vaccine platform technology**

The term “vaccine platform technology” broadly refers to a system that uses the same basic components as a backbone, but can be adapted for use against different pathogens by inserting new sequences.

**About “molecular clamp” vaccines**
Enveloped viruses, like influenza, have proteins on their surface that fuse to host cells during an infection. Although these surface proteins are antigenic—and therefore elicit an immune response—they are inherently unstable. One approach to vaccine design is to synthesise these proteins on their own such that they elicit an immune response, specifically antibodies, that can kill the virus. Unfortunately, they tend to change shape when expressed on their own, a shape that does not reflect the form of the protein on the virus surface. Consequently, the immune response that is induced with these vaccines does not produce antibodies that efficiently lock on to the virus. The University of Queensland has developed a process that can synthesise these surface proteins while “clamping” them into shape, making it easier for the immune system to induce a response that recognises them on the virus surface.

This synthetic antigen can then be purified and rapidly manufactured into a vaccine, within 16 weeks from pathogen identification.

This vaccine platform technology can be used to develop vaccines against a wide range of enveloped viruses (eg, Influenza, Ebola, MERS, Lassa virus, Measles, Herpes Simplex virus, Rabies).

The Molecular Clamp is patented technology developed by Professor Paul Young, Dr Keith Chappell, and Dr Dan Watterson.

The University of Queensland will be developing this vaccine platform in collaboration with The Commonwealth Scientific and Industrial Research Organisation (CSIRO) and a wider consortium including public sector and private sector partners in Australia, USA, and Asia.

About CEPI

CEPI is an innovative partnership between public, private, philanthropic, and civil organisations, launched at Davos in 2017, to develop vaccines to stop future epidemics. CEPI has reached over US$750 million of its $1 billion funding target. CEPI’s priority diseases include Ebola virus, Lassa virus, Middle East Respiratory Syndrome coronavirus, Nipah virus, Rift Valley Fever and Chikungunya virus. CEPI also invests in platform technologies that can be used for rapid vaccine and immunoprophylactic development against unknown pathogens (ie, Disease X). To date, CEPI has committed to investing over $456 million in vaccine and platform development. Learn more at www.cepi.net. Follow us at @CEPlvaccines.

About Inovio Pharmaceuticals, Inc.

Inovio is taking immunotherapy to the next level in the fight against cancer and infectious diseases. We are the only immunotherapy company that has reported generating CD8+ T cells in vivo in high quantity that are fully functional and whose killing capacity correlates with relevant clinical outcomes with a favorable safety profile. With an expanding portfolio of immune therapies, the company is advancing a growing clinical stage product pipeline, including candidates in Phase 3 and Phase 2. Partners and collaborators include MedImmune, Regeneron, Genentech, The Wistar Institute, University of Pennsylvania, the Parker Institute for Cancer Immunotherapy, DARPA, GeneOne Life Science, Plumbline Life Sciences, ApolloBio Corporation, Drexel University, NIH, HIV Vaccines Trial Network, National Cancer Institute, U.S. Military HIV Research Program, and Laval University. For more information, visit www.inovio.com.

About University of Queensland UQ rates in the global top 50 as measured by the Permance Ranking of Scientific Papers for World Universities and was recently rated 7th in Biotechnology world in the Shanghai Global Rankings of 2017. Professor Paul Young, Dr Keith Chappell, and Dr Dan Watterson have extensive expertise in molecular virology, viral pathogenesis and vaccine research.

About Moderna

Moderna is advancing messenger RNA (mRNA) science to create a new class of transformative medicines for patients. mRNA medicines are designed to direct the body’s cells to produce intracellular, membrane or secreted proteins that have a therapeutic or preventive benefit with the potential to address a broad spectrum of diseases. Moderna’s platform builds on continuous advances in basic and
applied mRNA science, delivery technology and manufacturing, providing the Company the capability to pursue in parallel a robust pipeline of new development candidates. Moderna is developing therapeutics and vaccines for infectious diseases, immuno-oncology, rare diseases and cardiovascular diseases, and autoimmune and inflammatory diseases, independently and with strategic collaborators.

Headquartered in Cambridge, Mass., Moderna currently has strategic alliances for development programs with AstraZeneca, Plc. (NASDAQ: AZN) and Merck, Inc. (NASDAQ: MRK), as well as the Defense Advanced Research Projects Agency (NASDAQ: DARPA), an agency of the U.S. Department of Defense and the Biomedical Advanced Research and Development Authority (BARDA), a division of the Office of the Assistant Secretary for Preparedness and Response (ASPR) within the U.S. Department of Health and Human Services (HHS). Moderna has been named a top biopharmaceutical employer by Science for the past five years. To learn more, visit www.modernatx.com.

For media enquiries, please contact:
Rachel Grant, Director of Communications and Advocacy, CEPI
Tel: (b) (6)
Email: (b) (6)

Mario Christodoulou, Communications and Advocacy Manager, CEPI
Tel: (b) (6)
Email: (b) (6)

Jodie Rogers, Communications Officer, CEPI
Tel: (b) (6)
Email: (b) (6)

Disclaimer: Any third-party material in this email has been shared for internal use under fair use provisions of U.S. copyright law, without further verification of its accuracy/veracity. It does not necessarily represent my views nor those of NIAID, NIH, HHS, or the U.S. government.
I am forwarding to Julie Ledgerwood et al.

Barney
To: Greten, Tim (NIH/NCI) [E] (b) (6)
Subject: RE: (b) (5) from COVID-19 patients

Hi Tim:

Hana Golding at FDA is looking for samples from COVID-19 infected patients. (b) (5) Thoughts?

Alison

-----Original Message-----
From: Greten, Tim (NIH/NCI) [E] (b) (6)
Sent: Wednesday, March 25, 2020 9:43 PM
To: List IMMUNI-L <IMMUNI-L@list.nih.gov>
Subject: (b) (5) from COVID-19 patients

All,

I am looking for a collaborator, who could help testing (b) (5) Any advice where and how this could be done is appreciated.

Tim


We have let NIAID know how we could spend any available CoV funds.

BG

Sent from my iPhone

On Jan 31, 2020, at 10:13 PM, Corbett, Kizzmekia (NIH/VRC) [E] wrote:

May they regret it forever.

Sent from the mobile device of:
Kizzmekia S. Corbett, PhD
Senior Research Fellow
NIH | NIAID | VRC
(919) 218-9101

From: "Graham, Barney (NIH/VRC) [E]"
Date: Friday, January 31, 2020 at 2:46:04 PM
To: "Corbett, Kizzmekia (NIH/VRC) [E]"
Cc: "Bok, Karin (NIH/VRC) [E]", "Morabito, Kaitlyn (NIH/VRC) [E]",
"Mascola, John (NIH/VRC) [E]", "Ledgerwood, Julie (NIH/NIAID) [E]",
"Daucher, Marybeth (NIH/NIAID) [E]"
Subject: Re: Wuhan virus response, proposal

That would have made them look pretty smart,
Interesting.

Sent from the mobile device of:
Kizzmekia S. Corbett, PhD
Senior Research Fellow
NIH | NIAID | VRC

From: "Bok, Karin (NIH/VRC) [E]"
Date: Friday, January 31, 2020 at 1:00:50 PM
To: "Corbett, Kizzmekia (NIH/VRC) [E]", "Morabito, Kaitlyn (NIH/VRC) [E]", "Graham, Barney (NIH/VRC) [E]"
Cc: "Mascola, John (NIH/VRC) [E]", "Ledgerwood, Julie (NIH/NIAID) [E]", "Daucher, Marybeth (NIH/NIAID) [E]"
Subject: FW: Wuhan virus response, proposal

Proposal from LID.

Karin Bok, MS, PhD
Senior Advisor, Vaccine Development
Office of the Director, Vaccine Research Center
National Institute of Allergy and Infectious Diseases
National Institutes of Health
phone: (b) (6)  mobile: (b) (6)  email: (b) (6)
https://www.niaid.nih.gov/about/vrc

From: Memoli, Matthew (NIH/NIAID) [E]
Sent: Friday, January 31, 2020 11:36 AM
To: Marston, Hilary (NIH/NIAID) [E]
Subject: FW: Wuhan virus response, proposal

Hi Hilary,

Just to keep you in the loop I wanted to let you know I sent the attached proposal to Steve Holland and DIR today (see below). Thought you might be interested to know about it.

Matt

--
Good morning,

In response to the current Wuhan virus outbreak, we have developed a proposal for [redacted]. Please let me know if you have any questions. We are certainly happy to supply a potential budget if you think this is something you may be able to support.

Thanks,
Matt

Matthew J. Memoli, M.D., M.S.
Director, LID Clinical Studies Unit
Laboratory of Infectious Diseases
National Institute of Allergy and Infectious Diseases
National Institutes of Health
MSC 3203 33 North Dr
Bethesda, MD 20892-3203
UNITED STATES
Email: (b)(6)
Phone: (b)(6)
Pager: (b)(6)

___________________________________________________________
Disclaimer: The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. National Institute of Allergy and Infectious Diseases shall not accept liability for any statements made that are sender’s own and not expressly made on behalf of NIAID.
Thanks for letting me know that Ken. It is remarkable that those two worlds came together for this.

Best wishes,
Barney

Hi Dr. Graham,

Thank you for sending the paper, it is very helpful both personally and professionally.

In regard to the trial, though I have not had much of a chance to speak with you directly, I know a lot of people are appreciative of the work that you do, and I just wanted to let you know that. and she is especially appreciative knowing that the first trials are taking place in our area. It is comforting for her to know this in the midst of being asked to work unexpectedly for much longer and unpredictable shifts, as those are now being asked to not report to work. While I never really expected the professional worlds to collide (VRC) it has lifted the spirits of many at her work knowing that something is taking place, even though this is only the start of the trial. Finally, thank you for sending the paper on the MERS-CoV, we were just talking about how durable COVID-19 and coronaviruses are in general. She has not received much guidance on protection, and the shortage of PPE is alarming.

Please take care and stay healthy!

Warmest regards,
Ken Abe

Ken Abe, Ph.D.
Senior Scientific Specialist
Vaccine Research Center, NIAID, NIH
office: mobile: NIH-001260
From: Graham, Barney (NIH/VRC) [E] (b)(6)
Sent: Monday, March 16, 2020 2:21 PM
To: VRC Bldg 40 Pl Plus <VRCP1Plus@mail.nih.gov>
Subject: CoV info

How to kill CoV

https://www.medrxiv.org/content/10.1101/2020.03.09.20033217v2

MERS CoV on environmental services – Attached

First trial participant enrolled about 12:30 EDT!


Barney

******************************
Barney S. Graham, MD, PhD
Senior Investigator
Deputy Director, Vaccine Research Center
Chief, Viral Pathogenesis Laboratory
National Institute of Allergy and Infectious Diseases, NIH
40 Convent Drive, MSC 3017
Bldg 40, Room 2502
Bethesda, MD 20892-3017
Phone: (b)(6)
URL: https://www.niaid.nih.gov/research/barney-graham-md-phd

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. National Institute of Allergy and Infectious Diseases shall not accept liability for any
statements made that are sender's own and not expressly made on behalf of the NIAID by one of its representatives.
Hi Kizzy,

We could probably

BG

Sent from my iPhone

> On Nov 13, 2019, at 11:59 AM, Corbett, Kizzmekia (NIH/VRC) [E] wrote:
  > Good morning Dr. Graham,
  > So I followed up with Lingshu, and we have a [Pathogens, IF 3.405] Special Issue "SARS-CoV Infections" - Invitation to publish a paper for free (PubMed, Scopus and SCIE)
  > What are your thoughts there?
  > --
  > Kizzmekia S. Corbett, PhD
  > Senior Research Fellow
  > National Institutes of Health
  > National Institutes of Allergy and Infectious Diseases
  > Vaccine Research Center
  > Viral Pathogenesis Laboratory
  > Building 40 Room 2608
  > 40 Convent Drive
  > Bethesda MD 20892
  > Laboratory: (b) (6)
  > Personal: (b) (6)
  > Fax: (301) 480-2777

> On 11/6/19, 4:28 PM, "Wang, Lingshu (NIH/VRC) [E]" wrote:
  > I am not sure whether the journal can accept our [Pathogens, IF 3.405] Special Issue "SARS-CoV Infections" - Invitation to publish a paper for free
Good afternoon,

Please let me know if this opportunity is useful to you.

Kizzmekia S. Corbett, PhD
Senior Research Fellow
National Institutes of Health
National Institutes of Allergy and Infectious Diseases Vaccine Research Center Viral Pathogenesis Laboratory

Building 40 Room 2608
40 Convent Drive
Bethesda MD 20892

Laboratory: [b] (6)
Personal: [b] (6)
Fax: (301) 480-2771

On 11/2/19, 3:21 PM, "Graham, Barney (NIH/VRC) [E]" wrote:

FYI. Is this helpful to you?

BG

From: Vanessa.Bu <vanessa.bu@ mdpi.com>
Sent: Thursday, October 31, 2019 2:32 AM
To: Graham, Barney (NIH/VRC) [E]
Cc: Pathogens Editorial Office <pathogens@ mdpi.com>; lgralinski@email.unc.edu
Subject: [Pathogens, IF 3.405] Special Issue "SARS-CoV Infections" - Invitation to publish a paper for free (PubMed, Scopus and SCIE)

Dear Dr. Graham,

Hope this email finds you well.

The journal Pathogens (ISSN 2076-0817, IF 3.405) is currently running a Special Issue entitled "SARS-CoV Infections". Dr. Lisa Gralinski is serving as the Guest Editor for this issue. According to her recommendation, we kindly invite you to contribute a feature paper to this special issue (**We will waive the full article processing charge 1300 CHF if your paper is accepted after peer review**):

For further reading, please follow the link to the Special Issue Website at:
https://www.mdpi.com/journal/pathogens/special_issues/SARS-CoV_Infections

Pathogens is an international, open access journal of pathogens and pathogen-host interactions published quarterly online by MDPI. Pathogens was covered by PubMed (PMC), Scopus (CiteScore 2018: 3.65 and SCIE)
(http://njl.clarivate.com/cgi-bin/jnlst/jlresults.cgi?PC=MASTER&Full=*pathogens).

We kindly invite you to learn more about our journal at http://www.mdpi.com/journal/pathogens.

Dr. Gralinski and I would be very pleased to receive your valuable contribution on the aforementioned topic.
for consideration of publication in this Special Issue. We welcome review articles, research articles or any other types. I am looking forward to hearing from you. If there are any questions or suggestions, please feel free to contact us.

Kind regards,
Vanessa Bu
Assistant Editor
From: Graham, Barney (NIH/VRC) [E]
Sent: Wed, 4 Mar 2020 14:02:48 +0000
To: William Dowling
Subject: Accepted: WHO Consultation on SARS-CoV-2 Reagents, Cross reactivity and immune Assays - Wed 3 PM CET
The HVTN/HPTN have placed into the field a natural history protocol to evaluate the immune responses post COVID-19 infection.

A draft of the study is enclosed. In short, it's a retrospective study of persons recovered from COVID-19, with 2 subsequent follow-ups about 4 weeks apart. A sister prospective study of infected persons is being drafted now and will also be started. This is, in essence, a vaccine preparedness study; looking to develop how do we differentiate vaccination from infection, as well as whether we can define any immune responses that differ by population groups.

This group is to talk about just what assays we should do and prioritize, and who are the best labs to involve in this endeavor. I suspect this discussion should be 90 minutes. I have asked Julie, Georgia and David to throw out a few main ideas to provide some structure to the discussion.
Thanks –

Larry
Here are a few answers below in red.

Although you didn't ask,

Barney

Thank you so much, Barney.
we would appreciate your perspective on these few questions:
If it would be easier to talk by phone, please let me know.  
Thank you so much.

Christine

Christine Grady
Chief, Department of Bioethics
NIH Clinical Center

From: Graham, Barney (NIH/VRC) [El
Sent: Tuesday, April 7, 2020 11:21 AM
To: Grady, Christine (NIH/CC/BEP) [El
Cc: Danis, Marion (NIH/CC/BEP) [El
Subject: Re: seeking your assistance

Hi Christine,

I'm a clinician and virologist, I'm glad to help if given those caveats you think I can.

Take care,

Barney

Sent from my iPhone

On Apr 7, 2020, at 10:53 AM, Grady, Christine (NIH/CC/BEP) [El < wrote:
HI Barney-

I hope you and yours are well and staying safe.

I am writing to see if you or someone else from VRC could help us.

Thank you very much,
Christine
From: Graham, Barney (NIH/VRC) [E]
Sent: Fri, 17 Jan 2020 02:56:15 +0000
To: Bushar, Nicholas (NIH/NIAID) [E]
Subject: Accepted: PRWG Update - Wuhan Coronavirus Outbreak
Hi Chris,

I am willing to talk periodically, but as you can see I may only episodically be able to keep up with emails so scheduling may be challenging.

Barney

Hi Barney,

If there is a short window during your commute or any free moment during your day/night, Bernie and I would really appreciate your feedback on?

Best,
Chris

From: Chris Twitty <(b)(6)>
Date: Tuesday, March 10, 2020 at 7:51 AM
To: "Graham, Barney (NIH/VRC) [E]" <(b)(6)>
Cc: Sandra Aung <(b)(6)>
Subject: Re: (b)(4) COVID-19?

Thank you very much for the details. This should allow us to get up and running

Best,

Chris

From: Graham, Barney (NIH/VRC) [E] <(b)(6)>
Sent: Tuesday, March 10, 2020 3:22:21 AM
To: Chris Twitty <(b)(6)>
Cc: Sandra Aung <(b)(6)>
Subject: Re: (b)(4) COVID-19?

Hi Chris,

Barney

Sent from my iPhone

On Mar 10, 2020, at 1:37 AM, Chris Twitty <(b)(6)> wrote:

Hi Barney,
Best,

Chris

From: "Graham, Barney (NIH/VRC) [E]"
Date: Wednesday, March 4, 2020 at 3:01 PM
To: Sandra Aung <(b) (6)>
Cc: Chris Twitty <(b) (6)>
Subject: Re: (b) (4) COVID-19?

How about now. I am just starting the drive home. You can call me at (b) (6)

Barney

Sent from my iPhone

On Mar 4, 2020, at 5:21 PM, Sandra Aung <(b) (6)> wrote:

Thanks Barney,

I believe Inovia was Oncosec’s parent company before Oncosec spun out to focus on oncology and yes I agree, (b) (4)

What time is good for you? I am copying Chris Twitty on this email so that we can all be on the call.

Best,
Sandra

From: Graham, Barney (NIH/VRC) [E] Sent: Wednesday, March 4, 2020 2:16 PM To: Sandra Aung Subject: Re: (b) (4) COVID-19?

Hi Sandra.
Nice to hear from you. Yes, things are a little more chaotic than usual around here. We’ve gotten off to a quick start on the new CoV outbreak.

I come to Scripps periodically. I’ll keep this in mind for next time.

Let me know if you want to schedule a call one evening while I’m driving home.

Best wishes,

Barney

---

On Mar 4, 2020, at 4:19 PM, Sandra Aung wrote:

Hi Barney!
Greetings from the far West! Thank you for the lovely family updates during the holidays, your family is growing so fast and bigger each year! I saw that you are participating in the World Vaccine Congress in Washington, very nice!

Not that I needed an excuse to reach out to you, I can imagine how busy you must be with the frenzy around coronavirus but would you have a few minutes to discuss this approach?

He would love to hear your feedback.

Best,

Sandra

BTW I live in now, will you be visiting this side of the world any time soon? Would love to catch up with you!
Karin or Gabi,

Could you convey what we suggest as options back to the Duke group? Thanks,

Barney

---

Kizzmekia S. Corbett, PhD
Senior Research Fellow | Scientific Lead
Coronavirus Vaccines & Immunopathogenesis (coVip) Team
Viral Pathogenesis Laboratory | Vaccine Research Center
National Institutes of Allergy and Infectious Diseases
National Institutes of Health

Building 40 Room 2608
40 Convent Drive
Bethesda MD 20892
Laboratory: 
Personal: 
Fax: (301) 480-2771
Hi VRC team,

In reviewing the research plan that Duke proposed,

Barney

Kaitlyn

Hi Judy,
Thanks for the update. I'm looping in Darren and Cynthia from Duke who are tracking this agreement for our IRB submission.

We would be happy to use that as a template to amend for additional research tools.

Best regards,

David

David Kordys, Ph.D.
DHVI Research Agreement Manager
Duke University
Office of Corporate Research Collaborations
2200 West Main Street, Suite 910B Durham, NC 27705
For Campus Mail:
P.O. Box 104025, Durham, NC 27710
Tel: (M, T, Th) and (W, F)

From: Stein, Judy (NIH/VRC) [C] (b)(6)
Sent: Wednesday, March 18, 2020 12:42 PM
To: David Kordys, Ph.D. (b)(6)>
Cc: Petrik, Amy (NIH/NIAID) [E] (b)(6)>; Morabito, Kaitlyn (NIH/VRC) [E] (b)(6)>; Bok, Karin (NIH/VRC) [E] (b)(6)>
Subject: RE: coronavirus (b)(4)

Hi David,
I think so – we will review and add our information.
Also, there is an RCA research plan that I was sent and need to read through and merge with our standard RCA template
And, we want to send more materials not covered in the -- I need to look at that and check with Amy but

Thanks,
Judy

From: David Kordys, Ph.D. (b)(6)>
Sent: Wednesday, March 18, 2020 12:16 PM
To: Stein, Judy (NIH/VRC) [C] (b)(6)>
Cc: Petrik, Amy (NIH/NIAID) [E] (b)(6)>; Morabito, Kaitlyn (NIH/VRC) [E] (b)(6)
Subject: RE: coronavirus (b)(4)

Hi All,
Hope all is well. I’m sure that each of you are also quite overloaded with COVID related agreements, but I wanted to reach out to see if you are the appropriate contact for the attached Research Collaboration Agreement. On Sunday, Bart sent me the attached agreement for review but did not provide the original email under which the document was provided. Since we all were involved in discussions regarding setting up a RCA between Duke and the NIAID, I thought reaching out to you would be a good start so as to move this process forward. If you would like to set up a time to discuss, please let me know. Email is fine as well.

Best regards,

David

David Kordys, Ph.D.
DHVI Research Agreement Manager
Duke University
Office of Corporate Research Collaborations
2200 West Main Street Suite 910B Durham, NC 27705
For Campus Mail:
P.O. Box 104025, Durham, NC 27710

From: Stein, Judy (NIH/VRC) [C] <](b)>(6)
Sent: Thursday, March 5, 2020 1:54 PM
To: David Kordys, Ph.D. <](b)>(6)
Cc: Petrik, Amy (NIH/NIAID) [E] <](b)>(6); Morabito, Kaitlyn (NIH/VRC) [E] <](b)>(6)
Subject: RE: coronavirus PMBC samples

Hi David,

How goes it. I will be gone next week but if Bart sends the research plan then Kaitlyn and Amy can help move this RCA through. It still takes about a week on our side for signatures but if you have any edits to the hRCA, please let us know. That can be finalized concurrent with the research plan.

Thanks,

Judy

From: Barton Haynes, M.D. <](b)>(6)
Sent: Wednesday, March 4, 2020 3:31 PM
To: Graham, Barney (NIH/VRC) [E] <](b)>(6); Marston, Hilary (NIH/NIAID) [E] <](b)>(6); Ledgerwood, Julie (NIH/NIAID) [E] <](b)>(6)
Cc: Degrace, Marciela (NIH/NIAID) [E] <](b)>(6); Gregory Sempowski <](b)>(6); Thomas Denny <](b)>(6); Kelly Soderberg <](b)>(6); Mascola, John (NIH/VRC) [E] <](b)>(6); David Kordys,
Hi Barney: thanks for this. I have cc’d this to David Kords here at Duke who is our tech transfer contact.

Just let us know what paper work needs to be done to get the [ ] but if not that many, we can study whatever is available. All the best Bart

Barton F. Haynes, M.D.
Director, Duke Human Vaccine Institute
Frederic M. Hanes Professor of Medicine and Immunology
2 Genome Court
MSRBII Bldg. Room 4090
DUMC 103020
Duke University Medical Center
Durham, NC 27710
Ph: [ ]
Fx: 919-684-5230

From: Graham, Barney (NIH/VRC) [E] [b][6]
Sent: Tuesday, March 3, 2020 11:41 AM
To: Marston, Hilary (NIH/NIAID) [E] [b][6]; Barton Haynes, M.D. [b][6]; Bozick, Brooke (NIH/OD) [E] [b][6]; Ledgerwood, Julie (NIH/NIAID) [E] [b][6]
Cc: Degrace, Marciela (NIH/NIAID) [E] [b][6]; Gregory Sempowski [b][6]; Thomas Denny [b][6]; Kelly Soderberg [b][6]; Mascola, John (NIH/VRC) [E] [b][6]
Subject: RE: coronavirus [b][4]
Adding John, Julie and Barney back to the string for responses. (bear with John and Barney if they are a bit delayed in responding today).

Hi Hilary, John and Barney:

Would be great to collaborate on this as well.

Many thanks for your consideration.

All the very best, Bart
From: Bozick, Brooke (NIH/OD) [E] <(b)(6)>
Sent: Saturday, February 29, 2020 12:39 PM
To: Barton Haynes, M.D. <(b)(6)>
Cc: Degrace, Mardela (NIH/NIAID) [E] <(b)(6); Marston, Hilary (NIH/NIAID) [E] <(b)(6)>; Gregory Sempowski <(b)(6)>; Thomas Denny <(b)(6)>; Kelly Soderberg <(b)(6)>
Subject: RE: coronavirus <(b)(4)>

Perfect, thank you Bart. I’ve added your information to our list.

I am only coordinating - Barney, John or Hilary would probably know more about accessing from the VRC.

Brooke

From: Barton Haynes, M.D. <(b)(6)>
Sent: Friday, February 28, 2020 7:08 AM
To: Bozick, Brooke (NIH/OD) [E] <(b)(6)>
Cc: Degrace, Mardela (NIH/NIAID) [E] <(b)(6); Marston, Hilary (NIH/NIAID) [E] <(b)(6)>; Gregory Sempowski <(b)(6)>; Thomas Denny <(b)(6)>; Kelly Soderberg <(b)(6)>
Subject: RE: coronavirus <(b)(4)>

Here you go Brooke. Let me know if you need any additional information.

Don’t know if it comes through on the form but we have an NIAID build Regional Biocontainment Lab at Duke with BSL-3+ capabilities.

Hilary and Brooke; we would also like I spoke with Barney and John re this as well.

We would like and stand ready to process both immediately.
All the very best Bart

From: Bozick, Brooke (NIH/OD) [E]  
Sent: Thursday, February 20, 2020 5:13 PM  
To: Barton Haynes, M.D.  
Cc: Degrace, Mardela (NIH/NIAID) [E]  
Subject: RE: coronavirus

Hi Bart,

My name is Brooke Bozick and I am serving as a NIAID point of contact for Your emailed was forwarded to me because we are compiling a list of investigator requests and working to assess I've attached the information request form for you to fill out so that we can add your request to our list. It will be very helpful if you could be as detailed as possible in terms of your scientific need and expected outcomes of the work.

Thank you,
Brooke Bozick

Brooke A. Bozick, Ph.D.
AAAS Science & Technology Policy Fellow, Health Scientist
Respiratory Diseases Branch
Division of Microbiology and Infectious Diseases
NIAID/NIH/DHHS
5601 Fishers Lane, Room 8A16, Rockville, MD 20852
Phone:

Begin forwarded message:  
From: "Barton Haynes, M.D."  
Date: February 17, 2020 at 4:02:18 PM EST  
To: "Marston, Hilary (NIH/NIAID) [E]"  
Cc: "Embry, Alan (NIH/NIAID) [E]", "Degrace, Mardela (NIH/NIAID) [E]"  
Subject: RE: coronavirus

Hi Hilary; would be great to have (we will take what we can get!)

All the very best Bart

From: Marston, Hilary (NIH/NIAID) [E]  
Sent: Monday, February 17, 2020 3:45 PM  
To: Barton Haynes, M.D.  
Cc: Embry, Alan (NIH/NIAID) [E] ; Degrace, Mardela (NIH/NIAID) [E]
Subject: Re: coronavirus

Bart - for listing purposes, how many

Thanks!

On Feb 17, 2020, at 2:53 PM, Graham, Barney (NIH/VRC) [E] <(b)(6)> wrote:

Hi Bart. (b)(4). This has been a painful process with so much urgency and so long a wait.

Best wishes,

Barney

Sent from my iPhone

On Feb 17, 2020, at 12:44 PM, Barton Haynes, M.D. <(b)(6)> wrote:

Hi Barney: In addition to what Greg Sempowski is doing with the (b)(4) (b)(4) (b)(4)

I realize most if not all of this is also being done there so more than happy to consider all this a direct collaboration. Our (b)(4) partner is Drew W and Norbert Pardi at Penn.

All the very best Bart

Barton F. Haynes, M.D.
Director, Duke Human Vaccine Institute
Frederic M. Hanes Professor of Medicine and Immunology
2 Genome Court

NIH-001286
FYI. This sounds like a useful educational project.

Barney

Sent from my iPhone

Begin forwarded message:

From: Scott Kennedy <scott@blackvalleyfilms.com>
Date: April 17, 2020 at 6:48:04 PM EDT
To: "Graham, Barney (NIH/VRC) [E]" (b)
Cc: Ché Landon <che@blackvalleyfilms.com>
Subject: Dr. Graham / Scott H. Kennedy Call IMMUNITY

Hi Barney,

First and foremost, thank you and your team for your tireless work, you've generated one of our most valuable resources - hope. I also wanted to congratulate you on the headway you and Moderna have made on launching your Covid 19 RNA vaccine trial.

I've been working on a documentary entitled IMMUNITY about the disconcerting rise of Vaccine Hesitancy and the detrimental ramifications of misinformation for over a year now with Dr. Peter Hotez and Dr. Paul Offit, both of whom speak extremely highly of you. We've also shot with Dr. Fauci and Dr. Nancy Messonnier, who were gracious with their time and expertise.

In light of the current pandemic, our project is more pertinent than ever and it's tantamount that we create media that provides respect for scientific truth, highlights the healing and humanitarian spirit that propels so much of medical advancement and dispels myths that fracture efforts to act communally and responsibly on behalf of the greater global good.

We'd love to set up a quick call to discuss resources, potential involvement and how we can support you now and beyond this pivotal moment in Vaccine History. I've included
a one page with project information below, and also cc'd our Director of Development, Ché Landon, who will be happy to coordinate.

Looking forward to connecting soon about IMMUNITY and thank you again for your unfathomable dedication.

Best,

Scott

--

Black Valley Films is the production company behind the Academy Award Nominated film, The Garden, Hulu’s Food Evolution, Showtime’s Fame High, Spirit Award Nominee OT: our town, and now Immunity.
Support for the importance of IMMUNITY

"Now more than ever we need to convince the public that there is so much at stake regarding the importance of vaccines, the dangers of outbreaks, and how to determine the truth. Documentaries are a wonderful way to do that, and Scott has proven with FOOD EVOLUTION that he is devoted to getting the science right!"

Dr. Paul Offit
PROFESSOR OF PEDIATRICS, DIVISION OF INFECTIOUS DISEASES, THE CHILDREN'S HOSPITAL OF PHILADELPHIA

"Scott's brilliant documentary FOOD EVOLUTION confirmed his special talent for communicating sound science in a compelling fashion. In Immunity he will vanquish misconceptions about vaccination with equal dispatch. The need is great. In locales across the country, vaccination refusal and hesitance have led to measles outbreaks. This timely project will save lives."

Kathleen Hall Jamieson, Ph.D.
DIRECTOR, ANNENBERG PUBLIC POLICY CENTER

Immunity's audience just went GLOBAL.

Before Covid-19, the Academy Award Nominated team at Black Valley Films saw the importance and necessity of telling the story of record-breaking global outbreaks, and how much Vaccine Hesitancy and Anti-Vaxxers have influenced not only those rising outbreaks, but how they've corroded many aspects of a long-trusted social contract to protect our communities. And with that, IMMUNITY, was born.

With the emergence of Covid 19 we find ourselves at an unrivaled advantage as filmmakers--having already cultivated relationships with top public health experts including the Head of the NIAID, Dr. Tony Fauci, vaccine experts Dr. Peter Hotez and Dr. Paul Offit, as well as Dr. Nancy Messonnier and her colleagues at the CDC.
Black Valley Films has been invited to a coveted seat at the table to capture history as it rapidly unfolds on the frontlines.

We need to ramp up production to track the answers to IMMUNITY'S most pressing questions: What will win: Science or disease? Truth or misinformation? The best of human nature or the worst of it?

IMMUNITY will highlight avenues of hope, dismantle obstacles to truth, and celebrate all those at the forefront of this pandemic as they courageously blaze the trail to collective recovery.

Black Valley Films needs to hit our $3 million goal to bring this essential piece of investigative journalism to full fruition. We have two key ways to support: A tax deductible contribution through our 501-(c)(3) sponsor, or as an Investor (including return on investment with interest, and pari passu backed participation with other investors).

---

Black Valley Films is the production company behind the Academy Award Nominated film, The Garden, Hulu’s Food Evolution, Showtime's Fame High, Spirit Award Nominee OT: our town, and now Immunity.

blackvalleyfilms.com
You can start there but

Barney

Should we

Thomas E. Royal Jr.
Deputy Chief, VAMB, VRC, NIAID
40 Convent Drive, Bethesda, MD 20892
Phone: 

Karin.

Karin Bok, MS, PhD
Senior Advisor, Vaccine Development
Office of the Director, Vaccine Research Center
National Institute of Allergy and Infectious Diseases
National Institutes of Health
phone: | mobile: | email: 

https://www.niaid.nih.gov/about/vrc
Hi Karin,

Thomas E. Royal Jr.
Deputy Chief, VAMB, VRC, NIAID
40 Convent Drive, Bethesda, MD 20892
Phone:

From: Graham, Barney (NIH/VRC) [E]  
Sent: Tuesday, April 28, 2020 4:18 PM
To: Royal, Thomas (NIH/NIAID) [E]  
Cc: Young, Monique (NIH/VRC) [E]  
Subject: Olu Abiona

Hi Thomas,

I would like to

Thanks,

Barney

***************************************
Barney S. Graham, MD, PhD
Senior Investigator
Deputy Director, Vaccine Research Center
Chief, Viral Pathogenesis Laboratory
National Institute of Allergy and Infectious Diseases, NIH
40 Convent Drive, MSC 3017
Bldg 40, Room 2502

NIH-001293
The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. National Institute of Allergy and Infectious Diseases shall not accept liability for any statements made that are sender's own and not expressly made on behalf of the NIAID by one of its representatives.
Barney

Sent from my iPhone

On Mar 23, 2020, at 11:10 AM, Mascola, John (NIH/VRC) wrote:

thanks

Confidential.

See attached. I needed this for my own reference, and figured your both did too.

--
Kizzmekia S. Corbett, PhD
Senior Research Fellow | Scientific Lead
Coronavirus Vaccines & Immunopathogenesis (coVip) Team
Viral Pathogenesis Laboratory | Vaccine Research Center
National Institutes of Allergy and Infectious Diseases
National Institutes of Health

Building 40 Room 2608
40 Convent Drive
Bethesda MD 20892
Laboratory: 
Personal:
Fax: (301) 480-2771
Hi Jonathan,

We are still working toward Barney

Sent from my iPhone

On Apr 10, 2020, at 3:16 AM, Gershoni, Jonathan wrote:

Hi Barney and Kaitlyn

We have completed the construction of our conformer library for Please let me know and if so how we can get some, thanks Jon

Prof. Jonathan M. Gershoni
Department of Cell Research and Immunology
Tel Aviv University
Tel Aviv 69978 ISRAEL
tel: (b) (6)
fax: 972 3 642 2046
website: http://gershoni.wixsite.com/labsite

NIH-001296
Hi Jon,

We are close to the same age, and agree that it feels like there is still quite a bit of life left, God willing. Good to hear your work is progressing. I’ve added Dr. Kizzmekia Corbett to the email because she is the scientific lead for our coronavirus work.

Best wishes,

Barney

Sent from my iPhone

On Feb 24, 2019, at 12:37 AM, Gershoni, Jonathan <b>(6)</b> wrote:

Hi Barney

How are you? Hopefully things are fine and you are happy and healthy!

Amazing to me is the fact that I must __________. However, as far as I am concerned this is just a chronological state and has no impact on my research. The University allows me to continue so long as I can fund my students and research. Thus far I am ok and doing well.

In any case, I would like to summarize our results and need some help.
What do you think, who might have some samples that I can get. Alternatively, I could probably send our

Thanks very much and looking forward to hearing from you,

Many thanks,

Jon

--------------
Prof. Jonathan M. Gershoni  
Department of Cell Research and Immunology  
Tel Aviv University  
Tel Aviv 59978 ISRAEL  
tel: (b)(4)  
fax: 972 3 642 2046  
website: http://gershoni.wixsite.com/labsite

From: Graham, Barney (NIH/VRC) [E]  
Sent: Thursday, August 18, 2016 16:14  
To: Gershoni, Jonathan  
Cc: Morabito, Kaitlyn (NIH/VRC) [F]  
Subject: Re: Need some help -- MERS research

Hi Jon.
Yes, we will put a package together for you.
Best wishes,
Barney

Sent from my iPhone

On Aug 18, 2016, at 8:44 AM, Gershoni, Jonathan [b][b] wrote:

Dear Dr. Graham:

We have met over the years in some of the HIV meetings and hope that you might be able to help me.

We have been studying the antibody - virus interaction in various human viral infections with the specific goal of characterizing the cognate epitopes of neutralizing antibodies. For this we have developed various combinatorial phage display technologies and a panel of computational
algorithms that allow us to predict conformational discontinuous epitopes and most recently analyze disease defining polyclonal sera from infected people.

Recently we have received an Israel Academy grant focused on (b) (4) which as you obviously can appreciate is a serious concern for Israel and the Middle East in general.

I was hoping that we might be able to obtain some of the (b) (4)

Obviously, I will be sure to process any MTA that would be required. Also if you can provide a (b) (4) that would be great.

Thanks very much for your consideration,

Best regards,

Jon

-----------------------------
Prof. Jonathan M. Gershoni
Department of Cell Research and Immunology
Tel Aviv University
Tel Aviv 69978 ISRAEL
tel: (b) (6)
fax: 972 3 642 2046
(b) (6)
Was that Jeff Cohen or Jeff Roberts from FDA or another Jeff?

BG

Sent from my iPhone

On Apr 23, 2020, at 11:43 AM, Sereti, Irini (NIH/NIAID) [E] <(b)(6)> wrote:

Dear Barney,

Totally up to you.

The person asking was Nisan Bhattacharyya from NIDCR according to the form.

I was very interested in Jeff’s question too about surrogates of protection, if we know.
Thank you again!

Hi Irini,

Do you want me to answer this question? Is there a place to send the answer?

BG
Had no time to ask you this... sorry!

From: "Roberts, Jacqueline (NIH/OD) [E]" (b)(6)
Date: Wednesday, April 22, 2020 at 3:48 PM
To: "Sereti, Irini (NIH/NIAID) [E]" (b)(6)
Cc: "Wanjek, Christopher (NIH/OD) [E]" (b)(6)
Subject: FW: Live Feedback for Rapid COVID-19 Vaccine Development: An Example of the Prototype Pathogen Approach for Pandemic Preparedness

From: NIH Videocast <videocast@mail.nih.gov>
Date: Wednesday, April 22, 2020 at 3:48 PM
To: "Roberts, Jacqueline (NIH/OD) [E]" (b)(6)
Subject: Live Feedback for Rapid COVID-19 Vaccine Development: An Example of the Prototype Pathogen Approach for Pandemic Preparedness

A message was received from the Videocast website

<table>
<thead>
<tr>
<th>From</th>
<th>Nisan Bhattacharyya</th>
</tr>
</thead>
<tbody>
<tr>
<td>Email</td>
<td></td>
</tr>
<tr>
<td>Organization</td>
<td>NIDCR</td>
</tr>
<tr>
<td>Phone</td>
<td></td>
</tr>
<tr>
<td>Subject</td>
<td></td>
</tr>
<tr>
<td>Message</td>
<td>If the current vaccine will be effective during receptor-independent non-endosomal viral entry or does it neutralize the virus extracellularly?</td>
</tr>
<tr>
<td>Received from</td>
<td>(b)(6)</td>
</tr>
<tr>
<td>Country</td>
<td>-</td>
</tr>
<tr>
<td>City</td>
<td>-</td>
</tr>
<tr>
<td>Region</td>
<td>-</td>
</tr>
<tr>
<td>ISP</td>
<td>Private IP Address LAN</td>
</tr>
<tr>
<td>Browser test</td>
<td></td>
</tr>
</tbody>
</table>

NIH-001301
From: Graham, Barney (NIH/VRC) [E]
Sent: Wed, 18 Mar 2020 22:14:40 +0000
To: Marston, Hilary (NIH/NIAID) [E]; Mascola, John (NIH/VRC) [E]
Cc: Bok, Karin (NIH/VRC) [E]; Gall, Jason (NIH/VRC) [C]
Subject: RE: Background information on Sanofi COVID-19 vaccine

BG

From: Marston, Hilary (NIH/NIAID) [E] (b)(6)>
Sent: Wednesday, March 18, 2020 5:42 PM
To: Mascola, John (NIH/VRC) [E] (b)(6)>
Cc: Graham, Barney (NIH/VRC) [E] (b)(6)>; Bok, Karin (NIH/VRC) [E] (b)(6)>; Gall, Jason (NIH/VRC) [C] (b)(6)
Subject: Re: Background information on Sanofi COVID-19 vaccine

On Mar 18, 2020, at 9:57 AM, Mascola, John (NIH/VRC) [E] (b)(6) wrote:

Hilary,
FYI and for our tracking. Note, (b)(5)

John

From: Lewin, Clement /US (b)(6)>
Sent: Wednesday, March 18, 2020 9:52 AM
To: Graham, Barney (NIH/VRC) [E] (b)(6)>; Mascola, John (NIH/VRC) [E] (b)(6)>; Mascola, John (NIH/VRC) [E] (b)(6)>
Cc: Sagar, Sangeetha /US (b)(6)>; Tartaglia, Jim /US (b)(6)>
Subject: Background information on Sanofi COVID-19 vaccine

NIH-001302
Jim Tartaglia asked me to provide you with a summary of our vaccine program. Please let me know if you have any questions.

Best wishes

Clem

Clement Lewin PhD MBA
Associate Vice President Head BARDA Office & NV Stakeholder Engagement
Sanofi Pasteur
38 Sidney Street, Cambridge MA 02139

Mobile: (b)(6)
Office: (b)(6)

------------------------------------------------------------------------------------------------------------------------

Cette communication (y compris les pièces jointes) est réservée à l'usage exclusif du destinataire (des destinataires) et peut contenir des informations privilégiées, confidentielles, exemptées de divulgation selon la loi ou protégées par les droits d'auteur. Si vous n'êtes pas un destinataire, toute utilisation, divulgation, distribution, reproduction, examen ou copie (totalement ou partiellement) est non-autorisée et peut être illégaux. Tout message électronique est susceptible d'altération et son intégrité ne peut être assurée. Sanofi Pasteur décline toute responsabilité au titre de ce message s'il a été modifié ou falsifié. Si vous n'êtes pas destinataire de ce message, merci de le détruire immédiatement et d'avertir l'expéditeur de l'erreur de distribution et de la destruction du message. Merci.

This transmission (including any attachments) is intended solely for the use of the addressee(s) and may contain confidential information including trade secrets which are privileged, confidential, exempt from disclosure under applicable law and/or subject to copyright. If you are not an intended recipient, any use, disclosure, distribution, reproduction, review or copying (either whole or partial) is unauthorized and may be unlawful. E-mails are susceptible to alteration and their integrity cannot be guaranteed. Sanofi Pasteur shall not be liable for this e-mail if modified or falsified. If you are not the intended recipient of this e-mail, please delete it immediately from your system and notify the sender of the wrong delivery and the mail deletion. Thank you.

------------------------------------------------------------------------------------------------------------------------

<SP One page summary of COVID-19 project 03 18 20 csl.docx>
From: Graham, Barney (NIH/VRC) [E]
Sent: Thu, 16 Apr 2020 11:48:32 +0000
To: Widge, Alicia (NIH/NIAID) [E]
Cc: Ledgerwood, Julie (NIH/NIAID) [E]; Gordon, Ingelise (NIH/VRC) [E]
Subject: RE: COVID+ Samples

Thanks,

BG

From: Widge, Alicia (NIH/NIAID) [E] <(b)(6)
Sent: Thursday, April 16, 2020 7:31 AM
To: Graham, Barney (NIH/VRC) [E] (b)(6)
Cc: Ledgerwood, Julie (NIH/NIAID) [E] (b)(6); Gordon, Ingelise (NIH/VRC) [E] (b)(6)
Subject: Re: COVID+ Samples

Ingelise found

Thanks,
Alicia

From: Widge, Alicia (NIH/NIAID) [E] (b)(6)
Sent: Wednesday, April 15, 2020 10:56 PM
To: Graham, Barney (NIH/VRC) [E]
Cc: Ledgerwood, Julie (NIH/NIAID) [E]; Gordon, Ingelise (NIH/VRC) [E]
Subject: Re: COVID+ Samples
Thanks, Eli has confirmed that his lab will process the samples.

I'm having trouble locating... I'll continue to work on it, but in the meantime, could you have them contact Ingelise first thing in the morning at...

Thank you,
Alicia

---

From: "Graham, Barney (NIH/VRC) [E]

Date: Wednesday, April 15, 2020 at 5:18 PM
To: "Widge, Alicia (NIH/NIAID) [E]"
Cc: "Ledgerwood, Julie (NIH/NIAID) [E]"
"Gordon, Ingelise (NIH/VRC) [E]"

Subject: Re: COVID+ Samples

and I will look into biosafety and sample processing.

BG

Sent from my iPhone

On Apr 15, 2020, at 3:39 PM, Widge, Alicia (NIH/NIAID) [E] wrote:

Hi Barney,

We are working to...

you can call or text me their name... or they can call Ingelise directly at...

Thank you,
Alicia
This is a very quick review. I think the list could be easily narrowed down to a top ten.

I highlighted some things I think could work (yellow) and some things that I don’t think will work (gray) and some things that should not be done (red/pink). Most have comments to explain thinking.

Barney

John, Barney,

I will look at this tonight as well.
Deliverables:

Let me know what you think,

Karin.

Karin Bok, MS, PhD
Senior Advisor, Vaccine Development
Office of the Director, Vaccine Research Center
National Institute of Allergy and Infectious Diseases
National Institutes of Health
phone: (b)(6) mobile: (b)(6) email: (b)(6)
https://www.niaid.nih.gov/about/vrc

From: "Donabedian, Armen (OS/ASPR/BARDA)" <(b)(6)>
Date: Tuesday, April 14, 2020 at 5:47 PM
To: Karin Bok <(b)(6)>, "Cassetti, Cristina (NIH/NIAID) [E]" <(b)(6)>, "Gerber, Susan I. (CDC/DDID/NCIRD/DVD)" <(b)(6)>, "Roberts, Jeff (FDA/CBER)"
Cc: "Arnold, Frank (OS/ASPR/BARDA) (CTR)" <(b)(6)>, "Houchens, Christopher (OS/ASPR/BARDA)" <(b)(6)>, "Johnson, Robert (OS/ASPR/BARDA)" <(b)(6)>, "Seals, Jonathan (OS/ASPR/BARDA)" <(b)(6)>, "Wolfe, Daniel (OS/ASPR/BARDA)"
Subject: Vaccine Assessment Table for Your Input

Dear Julia, Karin, Cristina, Sue and Jeff,

Here is the email I discussed with you all.
Thank you in advance, and please let us know if you have any questions.

Best regards from Armen, Dan, Frank and Jonathan.

[Vaccine Assessment Table v1.3.xlsx]
Armen M. Donabedian, PhD
Scientific Technical Advisor and Chief, Vaccines
Influenza and Emerging Infectious Diseases Division
Biomedical Advanced Research and Development Authority

Office: (b)(6)
Mobile: (b)(6)

(b)(6)
Karin,

BG

I will be there as well, for any questions, but agree that Kaitlyn should present.

Thanks

Karin.

Karin Bok, MS, PhD
Senior Advisor, Vaccine Development
Office of the Director, Vaccine Research Center
National Institute of Allergy and Infectious Diseases
National Institutes of Health
phone: (b)(6) mobile: (b)(6) email: (b)(6)
https://www.niaid.nih.gov/about/vrc

From: "Graham, Barney (NIH/VRC) [E]"
Date: Wednesday, April 15, 2020 at 4:48 PM
To: "Morabito, Kaitlyn (NIH/VRC) [E]"; "Corbett, Kizzmekia (NIH/VRC) [E]"; Karin Bok; "Carlton, Kevin (NIH/VRC) [E]"
Subject: RE: SARS-CoV-2 Vaccine Working Group
If you can attend that would be good.

Barney

From: Morabito, Kaitlyn (NIH/VRC) [E]
Sent: Wednesday, April 15, 2020 3:44 PM
To: Corbett, Kizzmekia (NIH/VRC) [E]; Bok, Karin (NIH/VRC) [E]; Carlton, Kevin (NIH/VRC) [E]; Graham, Barney (NIH/VRC) [E]; Modjarrad, Kayvon (NIH/VRC) [E]
Subject: FW: SARS-CoV-2 Vaccine Working Group

Kizzmekia and Barney

How would we like to handle this tomorrow. This is for the 2pm ASPR lead Vaccine working group meeting.

Thanks,
Kaitlyn

From: "Cassetti, Cristina (NIH/NIAID) [E]"
Date: Wednesday, April 15, 2020 at 2:41 PM
To: Kizzmekia Corbett [b][6]; Kaitlyn Morabito [b][6]; Kayvon Modjarrad [b][6]
Cc: "Stemmy, Erik (NIH/NIAID) [E]" [b][6]; "Taylor, Kimberly (NIH/NIAID) [E]" [b][6]; "Donabedian, Armen (OS/ASPR/BARDA)" [b][6]; Karin Bok [b][6]
Subject: FW: SARS-CoV-2 Vaccine Working Group

Hi Kizzmekia, Kaitlyn and Kayvon,

We have a Vaccine WG meeting tomorrow and VRC and WRAIR have been scheduled to give a brief update on your efforts in assay development- see attached agenda.

Would your respective groups be able to give a brief overview (5-10 min each) of your respective research on assay development, ideally with slides? Please let us know.

Thank you,
Cristina

From: Wolfe, Daniel (OS/ASPR/BARDA)
Hello everyone,

Please see the draft agenda and slide deck for Thursday’s SARS-CoV-2 Vaccine Working Group. Please let me know if you have any suggested changes to the agenda. Will provide an updated deck prior to the meeting if there additional slides.

Dan
Dear all,

You are invited to share progress and discuss issues relevant to the development of vaccines against COVID-19 on a weekly basis with your PHEMCE colleagues.

An agenda, presentation materials and supporting documents will be provided in advance of the meetings.

Many thanks in advance for your participation,

Armen, Cristina and Erik

***DO NOT DELETE OR CHANGE ANY OF THE TEXT BELOW THIS LINE***

Armen Donabedian has scheduled this WebEx meeting.

SARS-CoV-2 Vaccine Working Group
Host: Armen Donabedian

When it's time, start or join the WebEx meeting from here:

Access Information

Meeting Number: (b)(6)
Meeting Password: (b)(6)

Audio Connection

(b)(6) (Meeting Server Main Number)

Access Code: (b)(6)
Hosts, need your host access code or key? Go to the meeting information page:

Delivering the power of collaboration
The meetingserver.hhs.gov team
NIH's lead scientist for coronavirus vaccine research Kizzmekia Corbett lays out the government’s race to create a vaccine, saying they could be on track to have a vaccine from sequence to the general population within 8 months. [cnn.it/34DnXnV](https://cnn.it/34DnXnV) [pic.twitter.com/hlE34Wz64I](https://twitter.com/Sent from my iPhone)
RE: Tweet by Anderson Cooper 360° on Twitter

You said it much more eloquently than me.

My email attached just to Courtney.

Thanks Barney

I’m dropping Dr. Fauci from this email.
Le t me know if you would like to discuss in more detail.

Barney

---

Tony,

We will do so.

John

NIH-000144
NIH's lead scientist for coronavirus vaccine research Kizzmekia Corbett lays out the government’s race to create a vaccine, saying they could be on track to have a vaccine from sequence to the general population within 8 months. [cnn.it/34DnXnV](cnn.it/34DnXnV) [pic.twitter.com/hlE34Wz64I](pic.twitter.com/hlE34Wz64I) 4/14/20, 9:06 PM

Download the Twitter app

Sent from my iPhone